BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395. [PMID: 15565570 DOI: 10.1002/hep.20466] [Cited by in Crossref: 2409] [Cited by in F6Publishing: 2305] [Article Influence: 133.8] [Reference Citation Analysis]
Number Citing Articles
1 Fernandes DM, Pantangi V, Azam M, Salomao M, Iuga AC, Lefkowitch JH, Gill J, Morotti R, Lavine JE, Mencin AA. Pediatric Nonalcoholic Fatty Liver Disease in New York City: An Autopsy Study. The Journal of Pediatrics 2018;200:174-80. [DOI: 10.1016/j.jpeds.2018.04.047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
2 Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci 2010;55:560-78. [DOI: 10.1007/s10620-009-1081-0] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
3 Zhu JZ, Zhou QY, Wang YM, Dai YN, Zhu J, Yu CH, Li YM. Prevalence of fatty liver disease and the economy in China: A systematic review. World J Gastroenterol 2015; 21(18): 5695-5706 [PMID: 25987797 DOI: 10.3748/wjg.v21.i18.5695] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
4 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-32. [DOI: 10.1002/hep.23594] [Cited by in Crossref: 871] [Cited by in F6Publishing: 819] [Article Influence: 72.6] [Reference Citation Analysis]
5 Sanyal AJ. NASH: A global health problem: NASH: A global health problem. Hepatology Research 2011;41:670-4. [DOI: 10.1111/j.1872-034x.2011.00824.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
6 Tarantino G, Crocetto F, Di Vito C, Creta M, Martino R, Pandolfo SD, Pesce S, Napolitano L, Capone D, Imbimbo C. Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study. J Clin Med 2021;10:346. [PMID: 33477579 DOI: 10.3390/jcm10020346] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
7 Santos-Baez LS, Ginsberg HN. Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. Curr Opin Lipidol 2021;32:200-6. [PMID: 33883445 DOI: 10.1097/MOL.0000000000000756] [Reference Citation Analysis]
8 King CR, Rathouz PJ, Nicolae DL. An evolutionary framework for association testing in resequencing studies. PLoS Genet 2010;6:e1001202. [PMID: 21085648 DOI: 10.1371/journal.pgen.1001202] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
9 Yilmaz Y, Colak Y, Kurt R, Senates E, Eren F. Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back. Tumori 2013;99:10-6. [DOI: 10.1177/030089161309900102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
10 Lee T, Wu J, Yu S, Lin J, Wu M, Wu C. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer 2017;141:1307-14. [DOI: 10.1002/ijc.30784] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
11 Russo MW. Current concepts in the evaluation of patients for liver transplantation. Expert Review of Gastroenterology & Hepatology 2014;1:307-20. [DOI: 10.1586/17474124.1.2.307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Zelber-sagi S, Toker S, Armon G, Melamed S, Berliner S, Shapira I, Halpern Z, Santo E, Shibolet O. Elevated alanine aminotransferase independently predicts new onset of depression in employees undergoing health screening examinations. Psychol Med 2013;43:2603-13. [DOI: 10.1017/s0033291713000500] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
13 Jiang ZG, Mukamal K, Tapper E, Robson SC, Tsugawa Y. Low LDL-C and high HDL-C levels are associated with elevated serum transaminases amongst adults in the United States: a cross-sectional study. PLoS One 2014;9:e85366. [PMID: 24454851 DOI: 10.1371/journal.pone.0085366] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
14 Borges VFDAE, Diniz ALD, Cotrim HP, Rocha HLOG, Salomão FC. Dopplerfluxometria da veia hepática em pacientes com esteatose não alcoólica. Radiol Bras 2011;44:1-6. [DOI: 10.1590/s0100-39842011000100005] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
15 Foroughi M, Maghsoudi Z, Khayyatzadeh S, Ghiasvand R, Askari G, Iraj B. Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. Adv Biomed Res 2016;5:28. [PMID: 27014655 DOI: 10.4103/2277-9175.176368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
16 Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. Transplantation. 2011;91:684-689. [PMID: 21248661 DOI: 10.1097/tp.0b013e31820b6b84] [Cited by in Crossref: 105] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
17 Sorrentino P, Terracciano L, D’Angelo S, Ferbo U, Bracigliano A, Tarantino L, Perrella A, Perrella O, De Chiara G, Panico L. Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis. J Gastroenterol. 2010;45:1053-1062. [PMID: 20393861 DOI: 10.1007/s00535-010-0249-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
18 Stanislawski MA, Shaw J, Litkowski E, Lange EM, Perng W, Dabelea D, Lange LA. Genetic Risk for Hepatic Fat among an Ethnically Diverse Cohort of Youth: The Exploring Perinatal Outcomes among Children Study. J Pediatr 2020;220:146-153.e2. [PMID: 32143931 DOI: 10.1016/j.jpeds.2020.01.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Dharmalingam M, Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab. 2018;22:421-428. [PMID: 30090738 DOI: 10.4103/ijem.ijem_585_17] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
20 Ren XY, Shi D, Ding J, Cheng ZY, Li HY, Li JS, Pu HQ, Yang AM, He CL, Zhang JP, Ma YB, Zhang YW, Zheng TZ, Bai YN, Cheng N. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study. Lipids Health Dis 2019;18:47. [PMID: 30744645 DOI: 10.1186/s12944-019-0984-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
21 Kimura T, Deshpande GA, Urayama KY, Masuda K, Fukui T, Matsuyama Y. Association of weight gain since age 20 with non-alcoholic fatty liver disease in normal weight individuals. J Gastroenterol Hepatol 2015;30:909-17. [PMID: 25469977 DOI: 10.1111/jgh.12861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
22 Zhang Y, Zhang T, Zhang C, Tang F, Zhong N, Li H, Song X, Lin H, Liu Y, Xue F. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open. 2015;5:e008204. [PMID: 26395497 DOI: 10.1136/bmjopen-2015-008204] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
23 Ghapanchi J, Bazargani A, Khorshidi H, Erfani M, Rezazadeh F, Azad A, Derafshi R, Kalantari AH. Isolation and Identification of Non- Commensal Pathogenic Bacteria in the Saliva of Patients Candidate for Liver Transplant: A Cross Sectional Study in Shiraz, South of Iran. J Dent (Shiraz) 2020;21:81-6. [PMID: 32582821 DOI: 10.30476/DENTJODS.2019.77854.] [Reference Citation Analysis]
24 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 109] [Article Influence: 8.4] [Reference Citation Analysis]
25 Cox AJ, Wing MR, Carr JJ, Hightower RC, Smith SC, Xu J, Wagenknecht LE, Bowden DW, Freedman BI. Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus. Diabetes Metab. 2011;37:452-455. [PMID: 21665509 DOI: 10.1016/j.diabet.2011.05.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
26 Jun J, Polotsky VY. Metabolic consequences of sleep-disordered breathing. ILAR J 2009;50:289-306. [PMID: 19506316 DOI: 10.1093/ilar.50.3.289] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
27 DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, Blumenthal RS, Budoff MJ. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2013;227:429-436. [PMID: 23419204 DOI: 10.1016/j.atherosclerosis.2013.01.022] [Cited by in Crossref: 98] [Cited by in F6Publishing: 97] [Article Influence: 10.9] [Reference Citation Analysis]
28 Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine (Baltimore). 2017;96:e6770. [PMID: 28445310 DOI: 10.1097/md.0000000000006770] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
29 Carr RM, Patel RT, Rao V, Dhir R, Graham MJ, Crooke RM, Ahima RS. Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice. Am J Physiol Regul Integr Comp Physiol. 2012;302:R996-1003. [PMID: 22378776 DOI: 10.1152/ajpregu.00177.2011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
30 Corey KE, Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:1077-84; quiz e59-60. [PMID: 23962548 DOI: 10.1016/j.cgh.2013.08.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
31 Berk PD. Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology 2008;48:1362-76. [PMID: 18972439 DOI: 10.1002/hep.22632] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
32 Ahmed MH, Husain NE, Almobarak AO. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? J Family Med Prim Care. 2015;4:45-52. [PMID: 25810989 DOI: 10.4103/2249-4863.152252] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
33 Chaim FDM, Pascoal LB, Chaim FHM, Palma BB, Damázio TA, da Costa LBE, Carvalho R, Cazzo E, Gestic MA, Utrini MP, Milanski M, Chaim EA, Leal RF. Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. Sci Rep 2020;10:8496. [PMID: 32444690 DOI: 10.1038/s41598-020-65556-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
35 Rabiee B, Roozafzai F, Hemasi GR, Poustchi H, Keyvani H, Khonsari MR, Ajdarkosh H, Maadi M, Sima Saeedian F, Zamani F. The Prevalence of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus in an Iranian Population. Middle East J Dig Dis 2017;9:86-93. [PMID: 28638584 DOI: 10.15171/mejdd.2017.56] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
36 Wang S, Kamat A, Pergola P, Swamy A, Tio F, Cusi K. Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo. Metabolism 2011;60:1090-9. [PMID: 21310443 DOI: 10.1016/j.metabol.2010.12.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
37 Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 2014;34:e302-e307. [PMID: 24313922 DOI: 10.1111/liv.12429] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 10.5] [Reference Citation Analysis]
38 Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, Zhang R, McIntyre TM, Hazen SL. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res. 2010;51:3046-3054. [PMID: 20631297 DOI: 10.1194/jlr.m007096] [Cited by in Crossref: 170] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
39 Del Ben M, Baratta F, Polimeni L, Angelico F. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Intern Emerg Med. 2012;7 Suppl 3:S291-S296. [PMID: 23073870 DOI: 10.1007/s11739-012-0819-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
40 Huang CF, Chen JJ, Yeh ML, Huang CI, Hsieh MY, Yang HL, Dai CY, Huang JF, Lin ZY, Chen SC. PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. Sci Rep. 2015;5:11901. [PMID: 26139292 DOI: 10.1038/srep11901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
41 Ren X, Xia S, Zhang L, Li R, Zhou W, Ji R, Zhou J, Tian J, Zhan W. Analysis of liver steatosis analysis and controlled attenuation parameter for grading liver steatosis in patients with chronic hepatitis B. Quant Imaging Med Surg 2021;11:571-8. [PMID: 33532257 DOI: 10.21037/qims-19-1091] [Reference Citation Analysis]
42 Almobarak AO, Barakat S, Khalifa MH, Elhoweris MH, Elhassan TM, Ahmed MH. Non alcoholic fatty liver disease (NAFLD) in a Sudanese population: What is the prevalence and risk factors? Arab Journal of Gastroenterology 2014;15:12-5. [DOI: 10.1016/j.ajg.2014.01.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
43 Ibrahim SH, Hirsova P, Tomita K, Bronk SF, Werneburg NW, Harrison SA, Goodfellow VS, Malhi H, Gores GJ. Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes. Hepatology. 2016;63:731-744. [PMID: 26406121 DOI: 10.1002/hep.28252] [Cited by in Crossref: 108] [Cited by in F6Publishing: 114] [Article Influence: 15.4] [Reference Citation Analysis]
44 Persico M, Iolascon A. Steatosis as a co-factor in chronic liver diseases. World J Gastroenterol 2010; 16(10): 1171-1176 [PMID: 20222159 DOI: 10.3748/wjg.v16.i10.1171] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
45 Mohammadi F, Qorbani M, Kelishadi R, Baygi F, Ardalan G, Taslimi M, Mahmoudarabi M, Motlagh M, Asayesh H, Larijani B, Heshmat R. Association of Cardiometabolic Risk Factors and Hepatic Enzymes in a National Sample of Iranian Children and Adolescents: The CASPIAN-III Study. Journal of Pediatric Gastroenterology & Nutrition 2014;58:463-8. [DOI: 10.1097/mpg.0000000000000246] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
46 Guiu B, Petit J, Loffroy R, Aho S, Ben Salem D, Masson D, Robin I, Vergès B, Hillon P, Cercueil J, Krausé D. Liver methylene fraction by dual- and triple-echo gradient-echo imaging at 3.0T: Correlation with proton MR spectroscopy and estimation of robustness after SPIO administration. J Magn Reson Imaging 2011;33:119-27. [DOI: 10.1002/jmri.22390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
47 Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, Hu PJ. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007; 13(47): 6419-6424 [PMID: 18081233 DOI: 10.3748/wjg.v13.i47.6419] [Cited by in CrossRef: 111] [Cited by in F6Publishing: 125] [Article Influence: 7.4] [Reference Citation Analysis]
48 Maratos-Flier E. Fatty liver and FGF21 physiology. Exp Cell Res 2017;360:2-5. [PMID: 28549912 DOI: 10.1016/j.yexcr.2017.05.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
49 Kang HS, Okamoto K, Kim YS, Takeda Y, Bortner CD, Dang H, Wada T, Xie W, Yang XP, Liao G, Jetten AM. Nuclear orphan receptor TAK1/TR4-deficient mice are protected against obesity-linked inflammation, hepatic steatosis, and insulin resistance. Diabetes 2011;60:177-88. [PMID: 20864514 DOI: 10.2337/db10-0628] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 6.0] [Reference Citation Analysis]
50 Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am 2010;39:57-68. [PMID: 20202579 DOI: 10.1016/j.gtc.2009.12.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
51 Colak Y, Senates E, Ozturk O, Doganay HL, Coskunpinar E, Oltulu YM, Eren A, Sahin O, Ozkanli S, Enc FY. Association of serum lipoprotein-associated phospholipase A2 level with nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2012;10:103-109. [PMID: 22112193 DOI: 10.1089/met.2011.0111] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
52 Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444-450. [PMID: 18058083 DOI: 10.1007/s00125-007-0897-4] [Cited by in Crossref: 198] [Cited by in F6Publishing: 174] [Article Influence: 13.2] [Reference Citation Analysis]
53 Ioannou GN. The Role of Cholesterol in the Pathogenesis of NASH. Trends Endocrinol Metab. 2016;27:84-95. [PMID: 26703097 DOI: 10.1016/j.tem.2015.11.008] [Cited by in Crossref: 180] [Cited by in F6Publishing: 181] [Article Influence: 25.7] [Reference Citation Analysis]
54 Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894-903. [PMID: 20684021 DOI: 10.1002/hep.23759.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Fuyan S, Jing L, Wenjun C, Zhijun T, Weijing M, Suzhen W, Yongyong X. Fatty liver disease index: a simple screening tool to facilitate diagnosis of nonalcoholic fatty liver disease in the Chinese population. Dig Dis Sci. 2013;58:3326-3334. [PMID: 23900558 DOI: 10.1007/s10620-013-2774-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
56 Hall KC, Bernier SG, Jacobson S, Liu G, Zhang PY, Sarno R, Catanzano V, Currie MG, Masferrer JL. sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH. Proc Natl Acad Sci U S A 2019;116:11057-62. [PMID: 31085647 DOI: 10.1073/pnas.1821045116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
57 Ozturk A, Grajo JR, Gee MS, Benjamin A, Zubajlo RE, Thomenius KE, Anthony BW, Samir AE, Dhyani M. Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance. Ultrasound Med Biol 2018;44:2461-75. [PMID: 30232020 DOI: 10.1016/j.ultrasmedbio.2018.07.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
58 Rosenblatt R, Mehta A, Snell D, Hissong E, Kierans AS, Kumar S. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis. Dig Dis Sci. 2019;64:262-268. [PMID: 30269271 DOI: 10.1007/s10620-018-5295-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
59 Capitan V, Petit J, Aho S, Lefevre P, Favelier S, Loffroy R, Hillon P, Krausé D, Cercueil J, Guiu B. Macroscopic heterogeneity of liver fat: an MR-based study in type-2 diabetic patients. Eur Radiol 2012;22:2161-8. [DOI: 10.1007/s00330-012-2468-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
60 Ju UI, Jeong DW, Seo J, Park JB, Park JW, Suh KS, Kim JB, Chun YS. Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment. Cell Death Dis 2020;11:283. [PMID: 32332706 DOI: 10.1038/s41419-020-2472-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
61 Briseño-Bass P, Chávez-Pérez R, López-Zendejas M. Prevalence of hepatic steatosis and its relation to liver function tests and lipid profile in patients at medical check-up. Rev Gastroenterol Mex (Engl Ed) 2019;84:290-5. [PMID: 30292582 DOI: 10.1016/j.rgmx.2018.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
62 Andrade GCD, Fujise LH, Santana Filho JED, Oliveira F, Silva RDCMAD. Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study – sample of São José do Rio Preto. Rev Assoc Med Bras 2016;62:218-26. [DOI: 10.1590/1806-9282.62.03.218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
63 Ramirez R, Cohen JC, Hobbs HH, Browning JD. Hepatic triglyceride content in individuals with reduced intestinal cholesterol absorption due to variants in Nieman Pick C1-like 1. Hepatology 2011;54:736-7. [PMID: 21626528 DOI: 10.1002/hep.24461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
64 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
65 Link JC, Chen X, Arnold AP, Reue K. Metabolic impact of sex chromosomes. Adipocyte 2013;2:74-9. [PMID: 23805402 DOI: 10.4161/adip.23320] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
66 Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007;65:S57-S63. [PMID: 17605315 DOI: 10.1111/j.1753-4887.2007.tb00329.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 79] [Article Influence: 0.7] [Reference Citation Analysis]
67 Alkhouri N, McCullough AJ. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8:661-668. [PMID: 24683373 DOI: 10.1016/s0016-5085(10)62097-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Rivera CA. Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology 2008;15:109-14. [PMID: 18667295 DOI: 10.1016/j.pathophys.2008.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
69 Esteve E, Botas P, Delgado E, López-bermejo A, Lainez B, Engel P, Ricart W, Fernández-real J. Soluble TNF-α receptor 2 produced by alternative splicing is paradoxically associated with markers of liver injury. Clinical Immunology 2007;123:89-94. [DOI: 10.1016/j.clim.2006.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
70 Li H, Chen A, Shu L, Yu X, Gan L, Zhou L, Yang Z. Translocation of CIDEC in hepatocytes depends on fatty acids. Genes Cells 2014;19:793-802. [DOI: 10.1111/gtc.12180] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
71 Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, Liu Y, Kozlitina J, Stender S, Wood GC, Stepanchick AN, Still MD, McCarthy S, O'Dushlaine C, Packer JS, Balasubramanian S, Gosalia N, Esopi D, Kim SY, Mukherjee S, Lopez AE, Fuller ED, Penn J, Chu X, Luo JZ, Mirshahi UL, Carey DJ, Still CD, Feldman MD, Small A, Damrauer SM, Rader DJ, Zambrowicz B, Olson W, Murphy AJ, Borecki IB, Shuldiner AR, Reid JG, Overton JD, Yancopoulos GD, Hobbs HH, Cohen JC, Gottesman O, Teslovich TM, Baras A, Mirshahi T, Gromada J, Dewey FE. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018;378:1096-1106. [PMID: 29562163 DOI: 10.1056/nejmoa1712191] [Cited by in Crossref: 274] [Cited by in F6Publishing: 139] [Article Influence: 68.5] [Reference Citation Analysis]
72 Koliaki C, Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol. 2013;379:35-42. [PMID: 23770462 DOI: 10.1016/j.mce.2013.06.002] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 7.3] [Reference Citation Analysis]
73 Sam AH, Sleeth ML, Thomas EL, Ismail NA, Mat Daud N, Chambers E, Shojaee-Moradie F, Umpleby M, Goldstone AP, Le Roux CW, Bech P, Busbridge M, Laurie R, Cuthbertson DJ, Buckley A, Ghatei MA, Bloom SR, Frost GS, Bell JD, Murphy KG. Circulating pancreatic polypeptide concentrations predict visceral and liver fat content. J Clin Endocrinol Metab 2015;100:1048-52. [PMID: 25490276 DOI: 10.1210/jc.2014-3450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
74 Macaluso FS, Maida M, Petta S. Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World J Gastroenterol 2015; 21(39): 11088-11111 [PMID: 26494964 DOI: 10.3748/wjg.v21.i39.11088] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
75 Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013;5:1544-60. [PMID: 23666091 DOI: 10.3390/nu5051544] [Cited by in Crossref: 406] [Cited by in F6Publishing: 378] [Article Influence: 45.1] [Reference Citation Analysis]
76 Griffett K, Solt LA, El-Gendy Bel-D, Kamenecka TM, Burris TP. A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013;8:559-567. [PMID: 23237488 DOI: 10.1021/cb300541g] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
77 Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15:607. [PMID: 25894944 DOI: 10.1007/s11892-015-0607-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 8.7] [Reference Citation Analysis]
78 Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726-735. [PMID: 24316260 DOI: 10.1053/j.gastro.2013.11.049] [Cited by in Crossref: 443] [Cited by in F6Publishing: 422] [Article Influence: 49.2] [Reference Citation Analysis]
79 Lee JJ, Lambert JE, Hovhannisyan Y, Ramos-Roman MA, Trombold JR, Wagner DA, Parks EJ. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr 2015;101:34-43. [PMID: 25527748 DOI: 10.3945/ajcn.114.092262] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 10.8] [Reference Citation Analysis]
80 Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolaou N, van Houten EL, Visser JA, Morgan SA, Lavery GG. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013;154:4536-4547. [PMID: 24080367 DOI: 10.1210/en.2013-1592] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
81 Wang YG, Yang TL. Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway. Exp Ther Med 2015;10:1777-83. [PMID: 26640549 DOI: 10.3892/etm.2015.2741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
82 Siddiqui MS, Charlton M. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. Gastroenterology 2016;150:1849-62. [DOI: 10.1053/j.gastro.2016.02.077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
83 Petit JM, Guiu B, Duvillard L, Jooste V, Brindisi MC, Athias A, Bouillet B, Habchi M, Cottet V, Gambert P, Hillon P, Cercueil JP, Verges B. Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes. Clin Nutr 2012;31:520-5. [PMID: 22209679 DOI: 10.1016/j.clnu.2011.12.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
84 Szendroedi J, Chmelik M, Schmid AI, Nowotny P, Brehm A, Krssak M, Moser E, Roden M. Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology 2009;50:1079-86. [PMID: 19637187 DOI: 10.1002/hep.23093] [Cited by in Crossref: 126] [Cited by in F6Publishing: 114] [Article Influence: 9.7] [Reference Citation Analysis]
85 Wang S, Sheng F, Zou L, Xiao J, Li P. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism. J Adv Res 2021;34:109-22. [PMID: 35024184 DOI: 10.1016/j.jare.2021.06.001] [Reference Citation Analysis]
86 Podrini C, Koffas A, Chokshi S, Vinciguerra M, Lelliott CJ, White JK, Adissu HA, Williams R, Greco A. MacroH2A1 isoforms are associated with epigenetic markers for activation of lipogenic genes in fat-induced steatosis. FASEB J 2015;29:1676-87. [PMID: 25526730 DOI: 10.1096/fj.14-262717] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
87 Giard JM, Terrault NA. Women with Cirrhosis: Prevalence, Natural History, and Management. Gastroenterol Clin North Am. 2016;45:345-358. [PMID: 27261903 DOI: 10.1016/j.gtc.2016.02.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
88 Shin J, He M, Liu Y, Paredes S, Villanova L, Brown K, Qiu X, Nabavi N, Mohrin M, Wojnoonski K, Li P, Cheng HL, Murphy AJ, Valenzuela DM, Luo H, Kapahi P, Krauss R, Mostoslavsky R, Yancopoulos GD, Alt FW, Chua KF, Chen D. SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep. 2013;5:654-665. [PMID: 24210820 DOI: 10.1016/j.celrep.2013.10.007] [Cited by in Crossref: 166] [Cited by in F6Publishing: 145] [Article Influence: 18.4] [Reference Citation Analysis]
89 Basantani MK, Sitnick MT, Cai L, Brenner DS, Gardner NP, Li JZ, Schoiswohl G, Yang K, Kumari M, Gross RW. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res. 2011;52:318-329. [PMID: 21068004 DOI: 10.1194/jlr.m011205] [Cited by in Crossref: 148] [Cited by in F6Publishing: 96] [Article Influence: 12.3] [Reference Citation Analysis]
90 Kahali B, Halligan B, Speliotes EK. Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015;35:375-91. [PMID: 26676813 DOI: 10.1055/s-0035-1567870] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
91 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
92 Kim YJ, Park SY, Lee JH. Berteroin ameliorates lipid accumulation through AMPK-mediated regulation of hepatic lipid metabolism and inhibition of adipocyte differentiation. Life Sci 2021;282:119668. [PMID: 34087283 DOI: 10.1016/j.lfs.2021.119668] [Reference Citation Analysis]
93 Yeung MW, Wong GL, Choi KC, Luk AO, Kwok R, Shu SS, Chan AW, Lau ESH, Ma RCW, Chan HL, Chan JC, Wong VW, Kong AP. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. J Hepatol. 2017;. [PMID: 28989092 DOI: 10.1016/j.jhep.2017.09.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
94 Moore A, Wu L, Chuang JC, Sun X, Luo X, Gopal P, Li L, Celen C, Zimmer M, Zhu H. Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation. Hepatology 2019;69:1931-45. [PMID: 30584660 DOI: 10.1002/hep.30487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
95 Cho J, Koh Y, Han J, Kim D, Kim T, Kang H. Adiponectin mediates the additive effects of combining daily exercise with caloric restriction for treatment of non-alcoholic fatty liver. Int J Obes 2016;40:1760-7. [DOI: 10.1038/ijo.2016.104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
96 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285. [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x] [Cited by in Crossref: 1806] [Cited by in F6Publishing: 1693] [Article Influence: 164.2] [Reference Citation Analysis]
97 Moore JB. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proc Nutr Soc. 2019;78:290-304. [PMID: 30924429 DOI: 10.1017/s0029665119000570] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
98 Ahmed MH, Noor SK, Bushara SO, Husain NE, Elmadhoun WM, Ginawi IA, Osman MM, Mahmoud AO, Almobarak AO. Non-Alcoholic Fatty Liver Disease in Africa and Middle East: An Attempt to Predict the Present and Future Implications on the Healthcare System. Gastroenterology Res 2017;10:271-9. [PMID: 29118867 DOI: 10.14740/gr913w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
99 Bennet L, Groop L, Franks PW. Country of birth modifies the association of fatty liver index with insulin action in Middle Eastern immigrants to Sweden. Diabetes Res Clin Pract 2015;110:66-74. [PMID: 26278350 DOI: 10.1016/j.diabres.2015.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
100 Kallwitz E, Tayo BO, Kuniholm MH, Daviglus M, Zeng D, Isasi CR, Cotler SJ. Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos. Liver Int 2020;40:889-93. [PMID: 31965669 DOI: 10.1111/liv.14387] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
101 Fares R, Petta S, Lombardi R, Grimaudo S, Dongiovanni P, Pipitone R, Rametta R, Fracanzani AL, Mozzi E, Craxì A. The UCP2 -866 G& gt; A promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int. 2015;35:1574-1580. [PMID: 25351290 DOI: 10.1111/liv.12707] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
102 Huang X, Chen W, Yan C, Yang R, Chen Q, Xu H, Huang Y. Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression. Biomedicine & Pharmacotherapy 2019;118:109258. [DOI: 10.1016/j.biopha.2019.109258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
103 Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, Liu CJ, Wu MS, Shih SC. Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol 2014; 20(24): 7718-7729 [PMID: 24976709 DOI: 10.3748/wjg.v20.i24.7718] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
104 Corbin KD, Abdelmalek MF, Spencer MD, da Costa KA, Galanko JA, Sha W, Suzuki A, Guy CD, Cardona DM, Torquati A, Diehl AM, Zeisel SH. Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis. FASEB J 2013;27:1674-89. [PMID: 23292069 DOI: 10.1096/fj.12-219097] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
105 Spahis S, Alvarez F, Ahmed N, Dubois J, Jalbout R, Paganelli M, Grzywacz K, Delvin E, Peretti N, Levy E. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. The Journal of Nutritional Biochemistry 2018;58:28-36. [DOI: 10.1016/j.jnutbio.2018.03.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
106 Wang TC, Cominelli F, Fleischer DE, Gordon JM, Glickman RM, Limsui D, Mcquaid KR, Montrose M, Pasricha PJ, Powell DW, Rowe WA, Sandborn WJ, Todisco A. AGA Institute Future Trends Committee Report: The Future of Gastroenterology Training Programs in the United States. Gastroenterology 2008;135:1764-1789.e2. [DOI: 10.1053/j.gastro.2008.09.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
107 Willmes DM, Kurzbach A, Henke C, Schumann T, Zahn G, Heifetz A, Jordan J, Helfand SL, Birkenfeld AL. The longevity gene INDY ( I 'm N ot D ead Y et) in metabolic control: Potential as pharmacological target. Pharmacology & Therapeutics 2018;185:1-11. [DOI: 10.1016/j.pharmthera.2017.10.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
108 Mohammed H, Varoni EM, Cochis A, Cordaro M, Gallenzi P, Patini R, Staderini E, Lajolo C, Rimondini L, Rocchetti V. Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature. Biomedicines 2018;6:E115. [PMID: 30544974 DOI: 10.3390/biomedicines6040115] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 7.8] [Reference Citation Analysis]
109 Bhadoria AS, Kedarisetty CK, Bihari C, Kumar G, Jindal A, Bhardwaj A, Shasthry V, Vyas T, Benjamin J, Sharma S. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: A cross-sectional study. Liver Int. 2017;37:1397-1404. [PMID: 28231412 DOI: 10.1111/liv.13396] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
110 Velarde-Ruiz Velasco JA, García-Jiménez ES, García-Zermeño KR, Morel-Cerda EC, Aldana-Ledesma JM, Castro-Narro GE, Cerpa-Cruz S, Tapia-Calderón DK, Mercado-Jauregui LA, Contreras-Omaña R. Extrahepatic complications of non-alcoholic fatty liver disease: Its impact beyond the liver. Rev Gastroenterol Mex (Engl Ed) 2019;84:472-81. [PMID: 31488310 DOI: 10.1016/j.rgmx.2019.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
111 Sung KC, Lee MY, Lee JY, Lee SH, Kim JY, Wild SH, Byrne CD. Resolution of fatty liver and weight loss: Independent associations with changes in serum lipids and apolipoproteins. Atherosclerosis 2018;272:47-53. [PMID: 29547708 DOI: 10.1016/j.atherosclerosis.2018.03.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
112 Baulande S. [Polymorphisms in adiponutrin gene and association to hepatic steatosis]. Med Sci (Paris) 2009;25:130-2. [PMID: 19239840 DOI: 10.1051/medsci/2009252130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
113 Laukamp KR, Lennartz S, Ho V, Große Hokamp N, Zopfs D, Gupta A, Graner FP, Borggrefe J, Gilkeson R, Ramaiya N. Evaluation of the liver with virtual non-contrast: single institution study in 149 patients undergoing TAVR planning. Br J Radiol 2020;93:20190701. [PMID: 31825655 DOI: 10.1259/bjr.20190701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
114 Vonghia L, Michielsen P, Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int J Mol Sci. 2013;14:19867-19890. [PMID: 24084730 DOI: 10.3390/ijms141019867] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
115 Said A, Akhter A. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. Ann Hepatol. 2017;16:538-547. [PMID: 28611274 DOI: 10.5604/01.3001.0010.0284] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 12.5] [Reference Citation Analysis]
116 Starmann J, Fälth M, Spindelböck W, Lanz KL, Lackner C, Zatloukal K, Trauner M, Sültmann H. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One. 2012;7:e46584. [PMID: 23071592 DOI: 10.1371/journal.pone.0046584] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 6.6] [Reference Citation Analysis]
117 St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2009;24:399-407. [PMID: 19067776 DOI: 10.1111/j.1440-1746.2008.05694.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 4.6] [Reference Citation Analysis]
118 Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016;61:1356-1364. [PMID: 27017224 DOI: 10.1007/s10620-016-4079-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 11.7] [Reference Citation Analysis]
119 Saeed N, Glass LM, Habbal H, Mahmood A, Sengstock D, Saini SD, Tincopa MA. Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: a nationwide survey. Therap Adv Gastroenterol 2021;14:17562848211042200. [PMID: 34567270 DOI: 10.1177/17562848211042200] [Reference Citation Analysis]
120 Edelman RR. The history of MR imaging as seen through the pages of radiology. Radiology 2014;273:S181-200. [PMID: 25340436 DOI: 10.1148/radiol.14140706] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
121 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
122 Dixon LJ, Berk M, Thapaliya S, Papouchado BG, Feldstein AE. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest. 2012;92:713-723. [PMID: 22411067 DOI: 10.1038/labinvest.2012.45] [Cited by in Crossref: 92] [Cited by in F6Publishing: 95] [Article Influence: 9.2] [Reference Citation Analysis]
123 Levy R, Catana AM, Durbin-Johnson B, Halsted CH, Medici V. Ethnic differences in presentation and severity of alcoholic liver disease. Alcohol Clin Exp Res. 2015;39:566-574. [PMID: 25702770 DOI: 10.1111/acer.12660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.9] [Reference Citation Analysis]
124 Roldan-valadez E, Favila R, Martínez-lópez M, Uribe M, Méndez-sánchez N. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Annals of Hepatology 2008;7:212-20. [DOI: 10.1016/s1665-2681(19)31850-2] [Cited by in Crossref: 70] [Article Influence: 5.0] [Reference Citation Analysis]
125 Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology 2011;54:1496-9. [PMID: 22045667 DOI: 10.1002/hep.24612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
126 Harmon RC, Caldwell SH. Propensity for non-alcoholic fatty liver disease: more evidence for ethnic susceptibility. Liver International 2009;29:4-5. [DOI: 10.1111/j.1478-3231.2008.01959.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
127 Hwang YJ, Wi HR, Kim HR, Park KW, Hwang KA. Pinus densiflora Sieb. et Zucc. alleviates lipogenesis and oxidative stress during oleic acid-induced steatosis in HepG2 cells. Nutrients 2014;6:2956-72. [PMID: 25057104 DOI: 10.3390/nu6072956] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
128 Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna B. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593-1602. [PMID: 20222092 DOI: 10.1002/hep.23567] [Cited by in Crossref: 250] [Cited by in F6Publishing: 233] [Article Influence: 20.8] [Reference Citation Analysis]
129 Kirovski G, Schacherer D, Wobser H, Huber H, Niessen C, Beer C, Schölmerich J, Hellerbrand C. Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics. Int J Clin Exp Med. 2010;3:202-210. [PMID: 20827318 DOI: 10.1055/s-0029-1246560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
130 Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase-old biomarker and new concept: a review. Int J Med Sci 2014;11:925-35. [PMID: 25013373 DOI: 10.7150/ijms.8951] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 9.6] [Reference Citation Analysis]
131 Xu M, Zheng XM, Jiang F, Qiu WQ. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease. J Cell Biochem 2018;119:5864-74. [PMID: 29575055 DOI: 10.1002/jcb.26776] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
132 Herrigel DJ, Moss RA. Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. Postgrad Med. 2014;126:106-118. [PMID: 25414939 DOI: 10.3810/pgm.2014.10.2825] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
133 Huang DW, Lo YM, Chang WC, Lin CY, Chen JA, Wu JS, Huang WC, Shen SC. Alleviative effect of Ruellia tuberosa L. on NAFLD and hepatic lipid accumulation via modulating hepatic de novo lipogenesis in high-fat diet plus streptozotocin-induced diabetic rats. Food Sci Nutr 2020;8:5710-6. [PMID: 33133572 DOI: 10.1002/fsn3.1868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Argo CK, Caldwell SH. Epidemiology and Natural History of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009;13:511-31. [DOI: 10.1016/j.cld.2009.07.005] [Cited by in Crossref: 247] [Cited by in F6Publishing: 223] [Article Influence: 19.0] [Reference Citation Analysis]
135 Yeh MM. Nonalcoholic Fatty Liver Disease. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 435-40. [DOI: 10.1016/b978-0-443-06803-4.00031-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
136 Gastaldelli A, Basta G. Ectopic fat and cardiovascular disease: what is the link? Nutr Metab Cardiovasc Dis. 2010;20:481-490. [PMID: 20659791 DOI: 10.1016/j.numecd.2010.05.005] [Cited by in Crossref: 95] [Cited by in F6Publishing: 104] [Article Influence: 7.9] [Reference Citation Analysis]
137 Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, Weng X. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 2014;63:166-173. [PMID: 23978414 DOI: 10.1016/j.fct.2013.08.036] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 9.4] [Reference Citation Analysis]
138 Choi DH, Lee SJ, Kang CD, Park MO, Choi DW, Kim TS, Lee W, Cho BR, Kim YH, Lee BK, Ryu DR, Lee JW. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World J Gastroenterol 2013; 19(38): 6453-6457 [PMID: 24151364 DOI: 10.3748/wjg.v19.i38.6453] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
139 Gawrieh S, Baye TM, Carless M, Wallace J, Komorowski R, Kleiner DE, Andris D, Makladi B, Cole R, Charlton M. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2010;20:1698-1709. [PMID: 20473581 DOI: 10.1007/s11695-010-0171-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
140 Matsumoto T, Terai S, Oishi T, Kuwashiro S, Fujisawa K, Yamamoto N, Fujita Y, Hamamoto Y, Furutani-Seiki M, Nishina H, Sakaida I. Medaka as a model for human nonalcoholic steatohepatitis. Dis Model Mech 2010;3:431-40. [PMID: 20371730 DOI: 10.1242/dmm.002311] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
141 Paruk IM, Pirie FJ, Motala AA. Non-alcoholic fatty liver disease in Africa: A hidden danger. Glob Health Epidemiol Genom. 2019;4:e3. [PMID: 31019719 DOI: 10.1017/gheg.2019.2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
142 Petit JM, Masson D, Guiu B, Rollot F, Duvillard L, Bouillet B, Brindisi MC, Buffier P, Hillon P, Cercueil JP, Verges B. GCKR polymorphism influences liver fat content in patients with type 2 diabetes. Acta Diabetol 2016;53:237-42. [PMID: 25976242 DOI: 10.1007/s00592-015-0766-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
143 Panasevich MR, Meers GM, Linden MA, Booth FW, Perfield JW 2nd, Fritsche KL, Wankhade UD, Chintapalli SV, Shankar K, Ibdah JA, Rector RS. High-fat, high-fructose, high-cholesterol feeding causes severe NASH and cecal microbiota dysbiosis in juvenile Ossabaw swine. Am J Physiol Endocrinol Metab 2018;314:E78-92. [PMID: 28899857 DOI: 10.1152/ajpendo.00015.2017] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
144 Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:e279-e285. [PMID: 23158500 DOI: 10.1016/j.crohns.2012.10.015] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
145 Min YW, Kim Y, Gwak GY, Gu S, Kang D, Cho SJ, Guallar E, Cho J, Sinn DH. Non-alcoholic fatty liver disease and the development of reflux esophagitis: A cohort study. J Gastroenterol Hepatol 2018;33:1053-8. [PMID: 29131401 DOI: 10.1111/jgh.14042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
146 Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883-1894. [PMID: 21381068 DOI: 10.1002/hep.24283] [Cited by in Crossref: 560] [Cited by in F6Publishing: 532] [Article Influence: 50.9] [Reference Citation Analysis]
147 Wichro E, Macheiner T, Schmid J, Kavsek B, Sargsyan K. The Wide and Complex Field of NAFLD Biomarker Research: Trends. ISRN Hepatol 2014;2014:846923. [PMID: 27335843 DOI: 10.1155/2014/846923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
148 Feagins LA, Flores A, Arriens C, Park C, Crook T, Reimold A, Brown G. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol. 2015;27:1154-1160. [PMID: 26148245 DOI: 10.1097/meg.0000000000000421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
149 Wu JY, Tuomi A, Beland MD, Konrad J, Glidden D, Grand D, Merck D. Quantitative analysis of ultrasound images for computer-aided diagnosis. J Med Imaging (Bellingham) 2016;3:014501. [PMID: 26835502 DOI: 10.1117/1.JMI.3.1.014501] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
150 David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49:1904-1912. [PMID: 19434741 DOI: 10.1002/hep.22868] [Cited by in Crossref: 85] [Cited by in F6Publishing: 84] [Article Influence: 6.5] [Reference Citation Analysis]
151 Li X, Jiao Y, Xing Y, Gao P. Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis. Biomed Res Int. 2019;2019:5308308. [PMID: 31080822 DOI: 10.1155/2019/5308308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
152 Kramer H, Pickhardt PJ, Kliewer MA, Hernando D, Chen GH, Zagzebski JA, Reeder SB. Accuracy of Liver Fat Quantification With Advanced CT, MRI, and Ultrasound Techniques: Prospective Comparison With MR Spectroscopy. AJR Am J Roentgenol 2017;208:92-100. [PMID: 27726414 DOI: 10.2214/AJR.16.16565] [Cited by in Crossref: 90] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
153 Cusi K. Focus on the Type 2 Diabetes Patient with Liver Disease: Emphasis on Nonalcoholic Fatty Liver Disease (NAFLD). Endocrine Practice 2011;17:9-13. [DOI: 10.1016/s1530-891x(20)43146-5] [Reference Citation Analysis]
154 Shores NJ, Mendes-Corrêa MC, Maida I, Turner J, High KP, Babudieri S, Núãez M. Hepatic peroxisome proliferator-activated receptor γ and α-mRNA expression in HCV-infected adults is decreased by HIV co-infection and is also affected by ethnicity. Clinics (Sao Paulo) 2015;70:790-6. [PMID: 26735218 DOI: 10.6061/clinics/2015(12)05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
155 Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia–Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57-73. [DOI: 10.1038/s41575-018-0055-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 21.5] [Reference Citation Analysis]
156 Li C, Ye J, Prince M, Peng Y, Dou W, Shang S, Wu J, Luo X. Comparing mono-exponential, bi-exponential, and stretched-exponential diffusion-weighted MR imaging for stratifying non-alcoholic fatty liver disease in a rabbit model. Eur Radiol 2020;30:6022-32. [PMID: 32591883 DOI: 10.1007/s00330-020-07005-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA, Kim NH, Choi KM, Baik SH, Choi DS, Kim SG. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int. 2014;34:604-611. [PMID: 24382309 DOI: 10.1111/liv.12454] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
158 Gepner Y, Shelef I, Komy O, Cohen N, Schwarzfuchs D, Bril N, Rein M, Serfaty D, Kenigsbuch S, Zelicha H, Yaskolka Meir A, Tene L, Bilitzky A, Tsaban G, Chassidim Y, Sarusy B, Ceglarek U, Thiery J, Stumvoll M, Blüher M, Stampfer MJ, Rudich A, Shai I. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol 2019;71:379-88. [PMID: 31075323 DOI: 10.1016/j.jhep.2019.04.013] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 20.0] [Reference Citation Analysis]
159 Guiu B, Petit JM, Walker PM, Loffroy R, Hillon P, Brunotte F, Krausé D, Cercueil JP. [Magnetic resonance spectroscopy: a new standard for quantification of liver steatosis?]. Gastroenterol Clin Biol 2009;33:967-70. [PMID: 19646833 DOI: 10.1016/j.gcb.2009.05.011] [Reference Citation Analysis]
160 Chung GE, Cho EJ, Yoo JJ, Chang Y, Cho Y, Park SH, Shin DW, Han K, Yu SJ. Nonalcoholic fatty liver disease is associated with the development of obstructive sleep apnea. Sci Rep 2021;11:13473. [PMID: 34188101 DOI: 10.1038/s41598-021-92703-0] [Reference Citation Analysis]
161 Lamba R, Fananazapir G, Corwin MT, Khatri VP. Diagnostic Imaging of Hepatic Lesions in Adults. Surgical Oncology Clinics of North America 2014;23:789-820. [DOI: 10.1016/j.soc.2014.07.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
162 Kumar A, Blackshear C, Subauste JS, Esfandiari NH, Oral EA, Subauste AR. Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study. J Endocr Soc 2017;1:460-9. [PMID: 29264501 DOI: 10.1210/js.2017-00055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
163 Ormachea J, Parker KJ. A Preliminary Study of Liver Fat Quantification Using Reported Ultrasound Speed of Sound and Attenuation Parameters. Ultrasound Med Biol 2022:S0301-5629(21)00523-8. [PMID: 35039191 DOI: 10.1016/j.ultrasmedbio.2021.12.009] [Reference Citation Analysis]
164 Cho KY, Nakamura A, Omori K, Takase T, Miya A, Yamamoto K, Nomoto H, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig 2021;12:1272-7. [PMID: 33131199 DOI: 10.1111/jdi.13457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Muñoz LE, Cordero P, Torres L, Sauceda AY, Flores JP, Segura JJ. Adipokines in a group of mexican patients with nonalcoholic steatohepatitis. Annals of Hepatology 2009;8:123-8. [DOI: 10.1016/s1665-2681(19)31790-9] [Cited by in Crossref: 14] [Article Influence: 1.1] [Reference Citation Analysis]
166 Jung CH, Lee WJ, Hwang JY, Yu JH, Shin MS, Lee MJ, Jang JE, Leem J, Park JY, Kim HK. Assessment of the fatty liver index as an indicator of hepatic steatosis for predicting incident diabetes independently of insulin resistance in a Korean population. Diabet Med. 2013;30:428-435. [PMID: 23278318 DOI: 10.1111/dme.12104] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
167 Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861-867. [PMID: 19293782 DOI: 10.1038/ajg.2009.67] [Cited by in Crossref: 273] [Cited by in F6Publishing: 252] [Article Influence: 21.0] [Reference Citation Analysis]
168 Do HJ, Shin JS, Lee J, Lee YJ, Kim MR, Nam D, Kim EJ, Park Y, Suhr K, Ha IH. Association between liver enzymes and bone mineral density in Koreans: a cross-sectional study. BMC Musculoskelet Disord 2018;19:410. [PMID: 30474546 DOI: 10.1186/s12891-018-2322-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
169 Roldan-Valadez E, Favila R, Martínez-López M, Uribe M, Ríos C, Méndez-Sánchez N. In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. J Hepatol. 2010;53:732-737. [PMID: 20594607 DOI: 10.1016/j.jhep.2010.04.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
170 Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver. The Oncologist 2009;14:1095-105. [DOI: 10.1634/theoncologist.2009-0152] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
171 Liu DJ, Leal SM. Replication strategies for rare variant complex trait association studies via next-generation sequencing. Am J Hum Genet. 2010;87:790-801. [PMID: 21129725 DOI: 10.1016/j.ajhg.2010.10.025] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
172 Zhang H, Peng Y, Liu Z, Li S, Lv Z, Tian L, Zhu J, Zhao X, Chen M. Effects of Acupuncture Therapy on Abdominal Fat and Hepatic Fat Content in Obese Children: A Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy Study. The Journal of Alternative and Complementary Medicine 2011;17:413-20. [DOI: 10.1089/acm.2010.0322] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
173 Hu XN, Wang JF, Huang YQ, Wang Z, Dong FY, Ma HF, Bao ZJ. Huperzine A attenuates nonalcoholic fatty liver disease by regulating hepatocyte senescence and apoptosis: an in vitro study. PeerJ 2018;6:e5145. [PMID: 29967757 DOI: 10.7717/peerj.5145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
174 Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009;94:2537-43. [PMID: 19351729 DOI: 10.1210/jc.2009-0141] [Cited by in Crossref: 328] [Cited by in F6Publishing: 317] [Article Influence: 25.2] [Reference Citation Analysis]
175 Pierce AA, Duwaerts CC, Soon RK, Siao K, Grenert JP, Fitch M, Hellerstein MK, Beysen C, Turner SM, Maher JJ. Isocaloric manipulation of macronutrients within a high-carbohydrate/moderate-fat diet induces unique effects on hepatic lipogenesis, steatosis and liver injury. J Nutr Biochem 2016;29:12-20. [PMID: 26895660 DOI: 10.1016/j.jnutbio.2015.10.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
176 Khalil A, Cevik SE, Hung S, Kolla S, Roy MA, Suvorov A. Developmental Exposure to 2,2',4,4'-Tetrabromodiphenyl Ether Permanently Alters Blood-Liver Balance of Lipids in Male Mice. Front Endocrinol (Lausanne) 2018;9:548. [PMID: 30294300 DOI: 10.3389/fendo.2018.00548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
177 Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011;26:565-576. [PMID: 21947639 DOI: 10.1177/0884533611419668] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
178 Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, Chait A, Yeh MM, Quinn LS, Ioannou GN. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology. 2013;57:81-92. [PMID: 22508243 DOI: 10.1002/hep.25789] [Cited by in Crossref: 159] [Cited by in F6Publishing: 152] [Article Influence: 17.7] [Reference Citation Analysis]
179 Warren C, Carpenter AM, Neal D, Andreoni K, Sarosi G, Zarrinpar A. Racial Disparity in Liver Transplantation Listing. J Am Coll Surg 2021;232:526-34. [PMID: 33444709 DOI: 10.1016/j.jamcollsurg.2020.12.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
180 Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007;21:137-42. [PMID: 17493545 DOI: 10.1016/j.jdiacomp.2007.02.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
181 Sumida Y, Shima T, Mitsumoto Y, Katayama T, Umemura A, Yamaguchi K, Itoh Y, Yoneda M, Okanoue T. Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. Int J Mol Sci 2020;21:E4337. [PMID: 32570776 DOI: 10.3390/ijms21124337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
182 Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2009;25:230-237. [PMID: 19396962 DOI: 10.1097/MOG.0b013e3283294a18] [Cited by in Crossref: 54] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
183 Zeng F, Zhang Y, Han X, Zeng M, Gao Y, Weng J. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns. Front Immunol 2020;11:609900. [PMID: 33574818 DOI: 10.3389/fimmu.2020.609900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Li X, Qin P, Cao L, Lou Y, Shi J, Zhao P, Wang C, Ma J, Xu S, Peng X, Chen H, Zhao D, Hu F, Zhao Y. Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China. J Gastroenterol Hepatol 2021;36:1326-33. [PMID: 33001484 DOI: 10.1111/jgh.15286] [Reference Citation Analysis]
185 El-Koofy NM, Anwar GM, El-Raziky MS, El-Hennawy AM, El-Mougy FM, El-Karaksy HM, Hassanin FM, Helmy HM. The association of metabolic syndrome, insulin resistance and non-alcoholic fatty liver disease in overweight/obese children. Saudi J Gastroenterol. 2012;18:44-49. [PMID: 22249092 DOI: 10.4103/1319-3767.91738] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
186 Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol. 2013;48:1051-1060. [PMID: 23184095 DOI: 10.1007/s00535-012-0704-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
187 Reddy JK, Sambasiva Rao M. Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation. American Journal of Physiology-Gastrointestinal and Liver Physiology 2006;290:G852-8. [DOI: 10.1152/ajpgi.00521.2005] [Cited by in Crossref: 487] [Cited by in F6Publishing: 463] [Article Influence: 30.4] [Reference Citation Analysis]
188 Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, Loria P. Nonalcoholic fatty liver disease and aging: Epidemiology to management. World J Gastroenterol 2014; 20(39): 14185-14204 [PMID: 25339806 DOI: 10.3748/wjg.v20.i39.14185] [Cited by in CrossRef: 143] [Cited by in F6Publishing: 126] [Article Influence: 17.9] [Reference Citation Analysis]
189 Ma X, Holalkere NS, Kambadakone R A, Mino-Kenudson M, Hahn PF, Sahani DV. Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics. 2009;29:1253-1277. [PMID: 19755595 DOI: 10.1148/rg.295085186] [Cited by in Crossref: 196] [Cited by in F6Publishing: 162] [Article Influence: 15.1] [Reference Citation Analysis]
190 Petta S, Ciresi A, Bianco J, Geraci V, Boemi R, Galvano L, Magliozzo F, Merlino G, Craxì A, Giordano C. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS One 2017;12:e0186136. [PMID: 29161258 DOI: 10.1371/journal.pone.0186136] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
191 Nattenmüller J, Schlett CL, Tsuchiya N, Reeder SB, Pickhardt PJ, Kramer H, Kauczor H, Wielpütz MO, Seo JB, Hatabu H, van Beek EJ, Schiebler ML. Noncontrast Chest Computed Tomographic Imaging of Obesity and the Metabolic Syndrome: Part II Noncardiovascular Findings. Journal of Thoracic Imaging 2019;34:126-35. [DOI: 10.1097/rti.0000000000000393] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
192 Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabol Open 2021;12:100149. [PMID: 34870138 DOI: 10.1016/j.metop.2021.100149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
193 Patel PJ, Banh X, Horsfall LU, Hayward KL, Hossain F, Johnson T, Stuart KA, Brown NN, Saad N, Clouston A, Irvine KM, Russell AW, Valery PC, Williams S, Powell EE. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J 2018;48:144-51. [PMID: 29083080 DOI: 10.1111/imj.13667] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
194 Price JC, Wang R, Seaberg EC, Budoff MJ, Kingsley LA, Palella FJ, Witt MD, Post WS, Thio CL. The Association of Inflammatory Markers With Nonalcoholic Fatty Liver Disease Differs by Human Immunodeficiency Virus Serostatus. Open Forum Infect Dis 2017;4:ofx153. [PMID: 28929125 DOI: 10.1093/ofid/ofx153] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
195 Dufour DR. Alanine aminotransferase: is it healthy to be “normal”? Hepatology. 2009;50:1699-1701. [PMID: 19937679 DOI: 10.1002/hep.23358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
196 Umano GR, Martino M, Santoro N. The Association between Pediatric NAFLD and Common Genetic Variants. Children (Basel) 2017;4:E49. [PMID: 28629152 DOI: 10.3390/children4060049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
197 Remigio-Baker RA, Allison MA, Forbang NI, Loomba R, Anderson CAM, Budoff M, Schwimmer JB, Blumenthal RS, Ouyang P, Criqui MH. Race/ethnic and sex disparities in the non-alcoholic fatty liver disease-abdominal aortic calcification association: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2017;258:89-96. [PMID: 28235711 DOI: 10.1016/j.atherosclerosis.2016.11.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
198 Suh S, Choi S, Ahn H, Yang H, Kim Y, Sung N. The association between normal alanine aminotransferase levels and the metabolic syndrome: 2005 Korean National Health and Nutrition Examination Survey. Metabolism 2009;58:1731-6. [DOI: 10.1016/j.metabol.2009.05.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
199 Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103:71-83. [PMID: 19914930 DOI: 10.1093/qjmed/hcp158] [Cited by in Crossref: 392] [Cited by in F6Publishing: 366] [Article Influence: 30.2] [Reference Citation Analysis]
200 Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab 2011;96:885-93. [PMID: 21474685 DOI: 10.1210/jc.2010-2061] [Cited by in Crossref: 176] [Cited by in F6Publishing: 166] [Article Influence: 16.0] [Reference Citation Analysis]
201 Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081-1090. [PMID: 17654743 DOI: 10.1002/hep.21763] [Cited by in Crossref: 776] [Cited by in F6Publishing: 733] [Article Influence: 51.7] [Reference Citation Analysis]
202 Del Ben M, Polimeni L, Baratta F, Bartimoccia S, Carnevale R, Loffredo L, Pignatelli P, Violi F, Angelico F. Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver. Int J Hepatol 2014;2014:784985. [PMID: 24678423 DOI: 10.1155/2014/784985] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
203 Campbell PT, VanWagner LB, Colangelo LA, Lewis CE, Henkel A, Ajmera VH, Lloyd-Jones DM, Vaughan DE, Khan SS. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. Liver Int 2020;40:1111-20. [PMID: 32090434 DOI: 10.1111/liv.14417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
204 Bulum T, Kolarić B, Duvnjak L, Duvnjak M. Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci 2011;56:3655-63. [PMID: 21735081 DOI: 10.1007/s10620-011-1807-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
205 Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, Lee WM, Stolz A, Phillips T, Serrano J, Watkins PB; DILIN Investigators. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.Am J Gastroenterol. 2015;110:1450-1459. [PMID: 26346867 DOI: 10.1038/ajg.2015.283] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 9.1] [Reference Citation Analysis]
206 Xu XL, Jia H. Correlation between uric acid and nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2014; 22(7): 933-938 [DOI: 10.11569/wcjd.v22.i7.933] [Reference Citation Analysis]
207 Kim JC, Jeon JY, Yang WS, Kim CH, Eom DW. Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease. Curr Pharm Biotechnol 2019;20:222-31. [PMID: 30854954 DOI: 10.2174/1389201020666190311143554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
208 Gong Z, Tas E, Yakar S, Muzumdar R. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging. Mol Cell Endocrinol. 2017;455:115-130. [PMID: 28017785 DOI: 10.1016/j.mce.2016.12.022] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
209 Zhang X, Zhang Y, Gao W, Guo Z, Wang K, Liu S, Duan Z, Chen Y. Naringin improves lipid metabolism in a tissue-engineered liver model of NAFLD and the underlying mechanisms. Life Sci 2021;277:119487. [PMID: 33862107 DOI: 10.1016/j.lfs.2021.119487] [Reference Citation Analysis]
210 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 13.4] [Reference Citation Analysis]
211 Noh J, Kim Y, Gang G, Yang K, Lee H, Nguyen PH, Oh W, Song K, Lee C. Chestnut (Castanea crenata) inner shell extract inhibits development of hepatic steatosis in C57BL/6 mice fed a high-fat diet. Food Chemistry 2010;121:437-42. [DOI: 10.1016/j.foodchem.2009.12.061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
212 Liu Z, Cordoba-Chacon J, Kineman RD, Cronstein BN, Muzumdar R, Gong Z, Werner H, Yakar S. Growth Hormone Control of Hepatic Lipid Metabolism. Diabetes 2016;65:3598-609. [PMID: 27679560 DOI: 10.2337/db16-0649] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
213 Mashek DG, Greenberg AS. Serum TAG analysis differentiates between genetic and obesity-associated NAFLD. Diabetes 2014;63:42-4. [PMID: 24357693 DOI: 10.2337/db13-1500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
214 Cao Y, Wang C, Liu J, Liu ZM, Ling WH, Chen YM. Greater serum carotenoid levels associated with lower prevalence of nonalcoholic fatty liver disease in Chinese adults. Sci Rep 2015;5:12951. [PMID: 26256414 DOI: 10.1038/srep12951] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
215 Kwon EY, Kim YR, Kang DM, Yoon KH, Lee YH. Usefulness of US attenuation imaging for the detection and severity grading of hepatic steatosis in routine abdominal ultrasonography. Clin Imaging 2021;76:53-9. [PMID: 33549920 DOI: 10.1016/j.clinimag.2021.01.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
216 Mehta SR, Godsland IF, Thomas EL, Pavitt DV, Morin SX, Bell JD, Taylor-robinson SD, Johnston DG. Intrahepatic Insulin Exposure, Intrahepatocellular Lipid and Regional Body Fat in Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism 2012;97:2151-9. [DOI: 10.1210/jc.2011-2430] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
217 Lonardo A, Suzuki A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. J Clin Med 2020;9:E1278. [PMID: 32354182 DOI: 10.3390/jcm9051278] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
218 Zelber-Sagi S, Webb M, Assy N, Blendis L, Yeshua H, Leshno M, Ratziu V, Halpern Z, Oren R, Santo E. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol 2013; 19(1): 57-64 [PMID: 23326163 DOI: 10.3748/wjg.v19.i1.57] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 62] [Article Influence: 7.6] [Reference Citation Analysis]
219 Simental-Mendía M, Sánchez-García A, Rodríguez-Ramírez M, Simental-Mendía LE. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2021;163:105319. [PMID: 33246172 DOI: 10.1016/j.phrs.2020.105319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
220 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
221 Carulli N. Metabolic syndrome - cardiovascular disease risk and more. Aliment Pharmacol Ther 2005;22:1-2. [DOI: 10.1111/j.1365-2036.2005.02586.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
222 Zhan C, Olsen S, Zhang HC, Kannengiesser S, Chandarana H, Shanbhogue KP. Detection of hepatic steatosis and iron content at 3 Tesla: comparison of two-point Dixon, quantitative multi-echo Dixon, and MR spectroscopy. Abdom Radiol (NY). 2019;44:3040-3048. [PMID: 31286208 DOI: 10.1007/s00261-019-02118-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
223 Kappus M, Abdelmalek M. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. Clinics in Liver Disease 2017;21:321-35. [DOI: 10.1016/j.cld.2016.12.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
224 Xiao J, Xing F, Huo J, Fung ML, Liong EC, Ching YP, Xu A, Chang RC, So KF, Tipoe GL. Lycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis model. Sci Rep. 2014;4:5587. [PMID: 24998389 DOI: 10.1038/srep05587] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 8.4] [Reference Citation Analysis]
225 Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, Louden C, Tio F, Cusi K. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54:837-845. [PMID: 21674556 DOI: 10.1002/hep.24483] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
226 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Reference Citation Analysis]
227 Wicklow BA, Griffith AT, Dumontet JN, Venugopal N, Ryner LN, McGavock JM. Pancreatic lipid content is not associated with beta cell dysfunction in youth-onset type 2 diabetes. Can J Diabetes 2015;39:398-404. [PMID: 26099932 DOI: 10.1016/j.jcjd.2015.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
228 Wu HT, Lu FH, Ou HY, Su YC, Hung HC, Wu JS, Yang YC, Wu CL, Chang CJ. The role of hepassocin in the development of non-alcoholic fatty liver disease. J Hepatol 2013;59:1065-72. [PMID: 23792031 DOI: 10.1016/j.jhep.2013.06.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
229 Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic Fatty Liver Disease in Latinos. Clinical Gastroenterology and Hepatology 2016;14:5-12. [DOI: 10.1016/j.cgh.2015.05.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
230 Sung KC, Lee MY, Kim YH, Huh JH, Kim JY, Wild SH, Byrne CD. Obesity and incidence of diabetes: Effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver. Atherosclerosis 2018;275:50-7. [PMID: 29860108 DOI: 10.1016/j.atherosclerosis.2018.05.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
231 Zhao J, Jiao Y, Song Y, Liu J, Li X, Zhang H, Yang J, Lu Y. Stanniocalcin 2 Ameliorates Hepatosteatosis Through Activation of STAT3 Signaling. Front Physiol 2018;9:873. [PMID: 30038584 DOI: 10.3389/fphys.2018.00873] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
232 Lazo M, Mitchell MC. Epidemiology and Risk Factors for Alcoholic Liver Disease. In: Chalasani N, Szabo G, editors. Alcoholic and Non-Alcoholic Fatty Liver Disease. Cham: Springer International Publishing; 2016. pp. 1-20. [DOI: 10.1007/978-3-319-20538-0_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
233 Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, Hamdorf J, Adams LA. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. Am J Gastroenterol 2018;113:1484-93. [PMID: 29899440 DOI: 10.1038/s41395-018-0133-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
234 Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7(6): 846-858 [PMID: 25937862 DOI: 10.4254/wjh.v7.i6.846] [Cited by in Crossref: 166] [Cited by in F6Publishing: 148] [Article Influence: 23.7] [Reference Citation Analysis]
235 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49-59. [PMID: 27477080 DOI: 10.1016/j.trsl.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
236 Daudén E, Castañeda S, Suárez C, García-campayo J, Blasco A, Aguilar M, Ferrándiz C, Puig L, Sánchez-carazo J. Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermo-Sifiliográficas 2012;103:1-64. [DOI: 10.1016/s0001-7310(12)70001-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
237 Idilman IS, Ozdeniz I, Karcaaltincaba M. Hepatic Steatosis: Etiology, Patterns, and Quantification. Seminars in Ultrasound, CT and MRI 2016;37:501-10. [DOI: 10.1053/j.sult.2016.08.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
238 Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med 2008;18:6-14. [PMID: 18206803 DOI: 10.1016/j.tcm.2007.10.003] [Cited by in Crossref: 214] [Cited by in F6Publishing: 210] [Article Influence: 15.3] [Reference Citation Analysis]
239 van Tienhoven-Wind LJ, Dullaart RP. Low-normal thyroid function and novel cardiometabolic biomarkers. Nutrients 2015;7:1352-77. [PMID: 25690422 DOI: 10.3390/nu7021352] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
240 Min HK, Maruyama H, Jang BK, Shimada M, Mirshahi F, Ren S, Oh Y, Puri P, Sanyal AJ. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. FASEB J 2016;30:4071-82. [PMID: 27553225 DOI: 10.1096/fj.201600427R] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
241 Coilly A, Desterke C, Guettier C, Samuel D, Chiappini F. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis. Sci Rep 2019;9:19785. [PMID: 31874999 DOI: 10.1038/s41598-019-56235-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
242 Saiman Y, Hooks R, Carr RM. High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression. Curr Hepatology Rep 2020;19:412-9. [DOI: 10.1007/s11901-020-00539-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Kolwankar D, Vuppalanchi R, Ethell B, Jones DR, Wrighton SA, Hall SD, Chalasani N. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol. 2007;5:388-393. [PMID: 17368239 DOI: 10.1016/j.cgh.2006.12.021] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
244 Yue W, Sun X, Du T. Cholecystectomy versus central obesity or insulin resistance in relation to the risk of nonalcoholic fatty liver disease: the third US National Health and Nutrition Examination Survey. BMC Endocr Disord 2019;19:95. [PMID: 31477078 DOI: 10.1186/s12902-019-0423-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
245 Gleeson MW. Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia. Curr Treat Options Gastro 2019;17:378-93. [DOI: 10.1007/s11938-019-00241-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
246 Bouwman LMS, Swarts HJM, Fernández-Calleja JMS, van der Stelt I, Schols H, Oosting A, Keijer J, van Schothorst EM. Partial replacement of glucose by galactose in the post-weaning diet improves parameters of hepatic health. J Nutr Biochem 2019;73:108223. [PMID: 31665674 DOI: 10.1016/j.jnutbio.2019.108223] [Reference Citation Analysis]
247 Flamment M, Kammoun HL, Hainault I, Ferré P, Foufelle F. Endoplasmic reticulum stress: a new actor in the development of hepatic steatosis. Curr Opin Lipidol. 2010;21:239-246. [PMID: 20463471 DOI: 10.1097/mol.0b013e3283395e5c] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
248 Wicklow BA, Wittmeier KD, MacIntosh AC, Sellers EA, Ryner L, Serrai H, Dean HJ, McGavock JM. Metabolic consequences of hepatic steatosis in overweight and obese adolescents. Diabetes Care 2012;35:905-10. [PMID: 22357180 DOI: 10.2337/dc11-1754] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
249 Li D, Long W, Huang R, Chen Y, Xia M. 27‐Hydroxycholesterol Inhibits Sterol Regulatory Element‐Binding Protein 1 Activation and Hepatic Lipid Accumulation in Mice. Obesity 2018;26:713-22. [DOI: 10.1002/oby.22130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
250 Dassanayake AS, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakrawarthi S, De Silva AP, Makaya M, Mizoue T, Kato N, Wickremasinghe AR. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol. 2009;24:1284-1288. [PMID: 19476560 DOI: 10.1111/j.1440-1746.2009.05831.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 89] [Article Influence: 9.2] [Reference Citation Analysis]
251 Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 2009;284:26591-602. [PMID: 19638343 DOI: 10.1074/jbc.M109.022491] [Cited by in Crossref: 148] [Cited by in F6Publishing: 99] [Article Influence: 11.4] [Reference Citation Analysis]
252 Wu Q, Liu J, Liu L, Chen Y, Wang J, Leng L, Yu Q, Duan Z, Wang Y. Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver. ACS Biomater Sci Eng 2018;4:3016-26. [DOI: 10.1021/acsbiomaterials.8b00652] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
253 Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, Fletcher LM, Powell LW, Jonsson JR. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology. 2005;129:1937-1943. [PMID: 16344062 DOI: 10.1053/j.gastro.2005.09.015] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 7.1] [Reference Citation Analysis]
254 Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27-33. [PMID: 16799979 DOI: 10.1002/hep.21223] [Cited by in Crossref: 459] [Cited by in F6Publishing: 435] [Article Influence: 28.7] [Reference Citation Analysis]
255 Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T;  JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586-595. [PMID: 22328022 DOI: 10.1007/s00535-012-0533-z] [Cited by in Crossref: 268] [Cited by in F6Publishing: 232] [Article Influence: 26.8] [Reference Citation Analysis]
256 Setiawan VW, Lim U, Lipworth L, Lu SC, Shepherd J, Ernst T, Wilkens LR, Henderson BE, Le Marchand L. Sex and Ethnic Differences in the Association of Obesity With Risk of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2016;14:309-16. [PMID: 26404865 DOI: 10.1016/j.cgh.2015.09.015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
257 Jan T, Medvedev S, Cannon RM, Saggi B, Mcgee J, Paramesh A, Killackey M, Shores NJ, Slakey DP, Balart L, Buell JF. Racial disparity and their impact on hepatocellular cancer outcomes in inner-city New Orleans. Surgery 2012;152:661-7. [DOI: 10.1016/j.surg.2012.07.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
258 Chan R, Wong VW, Chu WC, Wong GL, Li LS, Leung J, Chim AM, Yeung DK, Sea MM, Woo J, Chan FK, Chan HL. Higher estimated net endogenous Acid production may be associated with increased prevalence of nonalcoholic Fatty liver disease in chinese adults in Hong Kong. PLoS One 2015;10:e0122406. [PMID: 25905490 DOI: 10.1371/journal.pone.0122406] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
259 Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58:676-683. [PMID: 23219442 DOI: 10.1016/j.jhep] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
260 Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015;5:147-158. [PMID: 26155043 DOI: 10.1016/j.jceh.2015.02.002] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
261 Chang E, Kim L, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Park CY. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats. World J Gastroenterol 2015; 21(25): 7754-7763 [PMID: 26167075 DOI: 10.3748/wjg.v21.i25.7754] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
262 Danford CJ, Iriana S, Shen C, Curry MP, Lai M. Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients. Liver Int 2019;39:1165-73. [PMID: 30809932 DOI: 10.1111/liv.14080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
263 Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, Deschenes M, Ghali P. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One. 2015;10:e0128774. [PMID: 26083565 DOI: 10.1371/journal.pone.0128774] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
264 Paredes AH, Torres DM, Harrison SA. Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2012;16:397-419. [DOI: 10.1016/j.cld.2012.03.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
265 Goran MI, Ventura EE. Genetic predisposition and increasing dietary fructose exposure: the perfect storm for fatty liver disease in Hispanics in the U.S. Dig Liver Dis 2012;44:711-3. [PMID: 22595618 DOI: 10.1016/j.dld.2012.04.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
266 Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv Aging 2021;16:1633-49. [PMID: 34548787 DOI: 10.2147/CIA.S295524] [Reference Citation Analysis]
267 Tota-Maharaj R, Blaha MJ, Zeb I, Katz R, Blankstein R, Blumenthal RS, Budoff MJ, Nasir K. Ethnic and sex differences in fatty liver on cardiac computed tomography: the multi-ethnic study of atherosclerosis. Mayo Clin Proc 2014;89:493-503. [PMID: 24613289 DOI: 10.1016/j.mayocp.2013.12.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
268 Iuliano AD, Feingold E, Wahed AS, Kleiner DE, Belle SH, Conjeevaram HS, Zmuda J, Liang TJ, Yee LJ; Virahep-C Study. Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 infection. Intervirology 2009;52:49-56. [PMID: 19401628 DOI: 10.1159/000214380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
269 Zhou J, Li H, Cai Y, Ma L, Mathews D, Lu B, Zhu B, Chen Y, Qian X, Xiao X, Li Q, Guo S, Huo Y, Zhao L, Tian Y, Li Q, Wu C. Mice lacking adenosine 2A receptor reveal increased severity of MCD-induced NASH. J Endocrinol 2019:JOE-19-0198. [PMID: 31505462 DOI: 10.1530/JOE-19-0198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
270 Miyake T, Kumagi T, Hirooka M, Furukawa S, Koizumi M, Tokumoto Y, Ueda T, Yamamoto S, Abe M, Kitai K. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. J Gastroenterol. 2013;48:413-422. [PMID: 22933183 DOI: 10.1007/s00535-012-0650-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
271 Itsiopoulos C, Marx W, Mayr H, Tatucu-babet O, Dash S, George E, Trakman G, Kelly J, Thomas C, Brazionis L. The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review. Journal of Nutrition & Intermediary Metabolism 2018;14:42-51. [DOI: 10.1016/j.jnim.2018.02.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
272 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 17.7] [Reference Citation Analysis]
273 Parker R, Weston CJ, Miao Z, Corbett C, Armstrong MJ, Ertl L, Ebsworth K, Walters MJ, Baumart T, Newland D, McMahon J, Zhang P, Singh R, Campbell J, Newsome PN, Charo I, Schall TJ, Adams DH. CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2018;314:G483-93. [PMID: 29420066 DOI: 10.1152/ajpgi.00213.2017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
274 Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci 2016;61:2108-17. [PMID: 26825843 DOI: 10.1007/s10620-016-4044-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
275 Kim JS, Lê KA, Mahurkar S, Davis JN, Goran MI. Influence of elevated liver fat on circulating adipocytokines and insulin resistance in obese Hispanic adolescents. Pediatr Obes 2012;7:158-64. [PMID: 22434756 DOI: 10.1111/j.2047-6310.2011.00014.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
276 Du G, Song Z, Zhang Q. Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med. 2013;57:31-37. [PMID: 23571185 DOI: 10.1016/j.ypmed.2013.03.011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
277 Saely CH, Vonbank A, Rein P, Woess M, Beer S, Aczel S, Jankovic V, Boehnel C, Risch L, Drexel H. Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. Clin Chim Acta 2008;397:82-6. [PMID: 18708042 DOI: 10.1016/j.cca.2008.07.024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
278 McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148-1155. [PMID: 25477264 DOI: 10.1016/j.jhep.2014.11.034] [Cited by in Crossref: 526] [Cited by in F6Publishing: 479] [Article Influence: 65.8] [Reference Citation Analysis]
279 Jiang ZG, Tapper EB, Kim M, Connelly MA, Krawczyk SA, Yee EU, Herman MA, Mukamal KJ, Lai M. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol 2018;52:444-51. [PMID: 28362682 DOI: 10.1097/MCG.0000000000000816] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
280 Wicklow B, Wittmeier K, T' Jong GW, McGavock J, Robert M, Duhamel T, Dolinsky VW. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol. Biochem Cell Biol 2015;93:522-30. [PMID: 26305052 DOI: 10.1139/bcb-2014-0136] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
281 Hugenholtz GC, Northup PG, Porte RJ, Lisman T. Is there a rationale for treatment of chronic liver disease with antithrombotic therapy? Blood Rev. 2015;29:127-136. [PMID: 25468718 DOI: 10.1016/j.blre.2014.10.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
282 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
283 Pompili S, Vetuschi A, Gaudio E, Tessitore A, Capelli R, Alesse E, Latella G, Sferra R, Onori P. Long-term abuse of a high-carbohydrate diet is as harmful as a high-fat diet for development and progression of liver injury in a mouse model of NAFLD/NASH. Nutrition 2020;75-76:110782. [PMID: 32268264 DOI: 10.1016/j.nut.2020.110782] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
284 Yracheta JM, Alfonso J, Lanaspa MA, Roncal-Jimenez C, Johnson SB, Sánchez-Lozada LG, Johnson RJ. Hispanic Americans living in the United States and their risk for obesity, diabetes and kidney disease: Genetic and environmental considerations. Postgrad Med 2015;127:503-10. [PMID: 25746679 DOI: 10.1080/00325481.2015.1021234] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
285 Pacifico L, Ferraro F, Bonci E, Anania C, Romaggioli S, Chiesa C. Upper limit of normal for alanine aminotransferase: quo vadis? Clin Chim Acta. 2013;422:29-39. [PMID: 23566931 DOI: 10.1016/j.cca.2013.03.030] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
286 Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670. [PMID: 19753129 DOI: 10.1155/2009/831670] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
287 Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int 2015;2015:460190. [PMID: 26273621 DOI: 10.1155/2015/460190] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 11.1] [Reference Citation Analysis]
288 Ashburn DD, Reed MJ. Gastrointestinal system and obesity. Crit Care Clin. 2010;26:625-627. [PMID: 20970047 DOI: 10.1016/j.ccc.2010.06.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
289 Fabbrini E, Conte C, Magkos F. Methods for assessing intrahepatic fat content and steatosis. Current Opinion in Clinical Nutrition & Metabolic Care 2009;12:474-81. [DOI: 10.1097/mco.0b013e32832eb587] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
290 Murakami S, Ono A, Kawasaki A, Takenaga T, Ito T. Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. Amino Acids 2018;50:1279-88. [PMID: 29946793 DOI: 10.1007/s00726-018-2605-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
291 Zambon A, Cusi K. The role of fenofibrate in clinical practice. Diabetes and Vascular Disease Research 2007;4:S15-20. [DOI: 10.3132/dvdr.2007.053] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
292 Ma D, Molusky MM, Song J, Hu CR, Fang F, Rui C, Mathew AV, Pennathur S, Liu F, Cheng JX. Autophagy deficiency by hepatic FIP200 deletion uncouples steatosis from liver injury in NAFLD. Mol Endocrinol. 2013;27:1643-1654. [PMID: 23960084 DOI: 10.1210/me.2013-1153] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
293 Hijmans BS, Grefhorst A, Oosterveer MH, Groen AK. Zonation of glucose and fatty acid metabolism in the liver: mechanism and metabolic consequences. Biochimie. 2014;96:121-129. [PMID: 23792151 DOI: 10.1016/j.biochi.2013.06.007] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 10.6] [Reference Citation Analysis]
294 Siddiqui MS, Patidar KR, Boyett S, Luketic VA, Puri P, Sanyal AJ. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2016;36:572-9. [PMID: 26713759 DOI: 10.1111/liv.13054] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
295 Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47:1916-1923. [PMID: 18433022 DOI: 10.1002/hep.22241] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 7.5] [Reference Citation Analysis]
296 Luersen GF, Bhosale P, Szklaruk J. State-of-the-art cross-sectional liver imaging: beyond lesion detection and characterization. J Hepatocell Carcinoma 2015;2:101-17. [PMID: 27508199 DOI: 10.2147/JHC.S85201] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
297 Sesti G, Fiorentino TV, Arturi F, Perticone M, Sciacqua A, Perticone F. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PLoS One. 2014;9:e88569. [PMID: 24520400 DOI: 10.1371/journal.pone.0088569] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
298 Sauvage VR, Levene AP, Nguyen HT, Wood TC, Kudo H, Concas D, Thomas HC, Thursz MR, Goldin RD, Anstee QM, Elson DS. Multi-excitation fluorescence spectroscopy for analysis of non-alcoholic fatty liver disease. Lasers Surg Med 2011;43:392-400. [PMID: 21674544 DOI: 10.1002/lsm.21064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
299 Sourianarayanane A, Arikapudi S, McCullough AJ, Humar A. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation. Eur J Gastroenterol Hepatol. 2017;29:481-487. [PMID: 28253211 DOI: 10.1097/meg.0000000000000820] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
300 Nakadate K, Motojima K, Tanaka-nakadate S. Dilatation of Sinusoidal Capillary and Swelling of Sinusoidal Fenestration in Obesity: An Ultrastructural Study. Ultrastructural Pathology 2013;39:30-7. [DOI: 10.3109/01913123.2014.947010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
301 Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep. 2007;7:175-180. [PMID: 17547834 DOI: 10.1007/s11892-007-0029-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
302 Dioguardi Burgio M, Ronot M, Reizine E, Rautou P, Castera L, Paradis V, Garteiser P, Van Beers B, Vilgrain V. Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. Eur Radiol 2020;30:2293-301. [DOI: 10.1007/s00330-019-06480-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
303 Lin WT, Yang KC, Chen YT, Huang KC, Yang WS. Elevated serum S14 levels are associated with more severe liver steatosis by ultrasonography. Sci Rep 2021;11:24181. [PMID: 34921174 DOI: 10.1038/s41598-021-03279-8] [Reference Citation Analysis]
304 Hutton C, Gyngell ML, Milanesi M, Bagur A, Brady M. Validation of a standardized MRI method for liver fat and T2* quantification. PLoS One 2018;13:e0204175. [PMID: 30235288 DOI: 10.1371/journal.pone.0204175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
305 Hanzel J, Ma C, Casteele NV, Khanna R, Jairath V, Feagan BG. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs 2021;81:333-47. [PMID: 33400241 DOI: 10.1007/s40265-020-01460-3] [Reference Citation Analysis]
306 Scribner KB, Pawlak DB, Ludwig DS. Hepatic steatosis and increased adiposity in mice consuming rapidly vs. slowly absorbed carbohydrate. Obesity (Silver Spring) 2007;15:2190-9. [PMID: 17890486 DOI: 10.1038/oby.2007.260] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
307 Pinidiyapathirage MJ, Dassanayake AS, Rajindrajith S, Kalubowila U, Kato N, Wickremasinghe AR, de Silva HJ. Non-alcoholic fatty liver disease in a rural, physically active, low income population in Sri Lanka. BMC Res Notes. 2011;4:513. [PMID: 22115060 DOI: 10.1186/1756-0500-4-513] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
308 Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N;  Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012;55:769-780. [PMID: 21987488 DOI: 10.1002/hep.24726] [Cited by in Crossref: 130] [Cited by in F6Publishing: 125] [Article Influence: 13.0] [Reference Citation Analysis]
309 Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018;113:1649-1659. [PMID: 29880964 DOI: 10.1038/s41395-018-0088-6] [Cited by in Crossref: 181] [Cited by in F6Publishing: 167] [Article Influence: 45.3] [Reference Citation Analysis]
310 McNear S, Harrison SA. Current status of therapy in nonalcoholic Fatty liver disease. Therap Adv Gastroenterol. 2009;2:29-43. [PMID: 21180532 DOI: 10.1177/1756283x08100327] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
311 Kantartzis K, Rettig I, Staiger H, Machann J, Schick F, Scheja L, Gastaldelli A, Bugianesi E, Peter A, Schulze M, Fritsche A, Häring H, Stefan N. An extended fatty liver index to predict non-alcoholic fatty liver disease. Diabetes & Metabolism 2017;43:229-39. [DOI: 10.1016/j.diabet.2016.11.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
312 Saab S, Phan J, Jimenez MA, Grotts JF, Walters L, Hathaway KA, Patel KR, Lankarani A, Herman M, Holloman DA, Nieto JM. Endoscopic Ultrasound Liver Biopsies Accurately Predict the Presence of Fibrosis in Patients With Fatty liver. Clin Gastroenterol Hepatol. 2017;15:1477-1478. [PMID: 28419859 DOI: 10.1016/j.cgh.2017.04.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
313 Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013;62:352-60. [DOI: 10.1016/j.metabol.2012.08.005] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 10.0] [Reference Citation Analysis]
314 Cai Y, Li H, Liu M, Pei Y, Zheng J, Zhou J, Luo X, Huang W, Ma L, Yang Q, Guo S, Xiao X, Li Q, Zeng T, Meng F, Francis H, Glaser S, Chen L, Huo Y, Alpini G, Wu C. Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity. Hepatology 2018;68:48-61. [PMID: 29315766 DOI: 10.1002/hep.29777] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
315 Houghton-Rahrig LD, Schutte DL, von Eye A, Fenton JI, Given BA, Hord NG. Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease. Nurs Outlook 2013;61:242-251.e2. [PMID: 23849554 DOI: 10.1016/j.outlook.2013.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
316 Alam S, Noor-E-Alam SM, Chowdhury ZR, Alam M, Kabir J. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J Hepatol 2013; 5(5): 281-287 [PMID: 23717739 DOI: 10.4254/wjh.v5.i5.281] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
317 Earl TM, Nicoud IB, Pierce JM, Wright JP, Majoras NE, Rubin JE, Pierre KP, Gorden DL, Chari RS. Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Ann Surg Oncol 2009;16:1043-50. [PMID: 19165543 DOI: 10.1245/s10434-009-0325-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
318 Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit 2012;18:CR735-40. [PMID: 23197236 DOI: 10.12659/msm.883601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
319 Mojiminiyi OA, Abdella NA, Al Mohammedi H. Higher levels of alanine aminotransferase within the reference range predict unhealthy metabolic phenotypes of obesity in normoglycemic first-degree relatives of patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2010;12:301-8. [PMID: 20433554 DOI: 10.1111/j.1751-7176.2009.00238.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
320 Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: An update. World J Gastroenterol 2014; 20(27): 9050-9054 [PMID: 25083078 DOI: 10.3748/wjg.v20.i27.9050] [Cited by in F6Publishing: 42] [Reference Citation Analysis]
321 Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Sourianarayanane A, Khiyami A, Yerian L, Pai R, McCullough AJ, Dasarathy S. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int. 2015;35:979-985. [PMID: 24905085 DOI: 10.1111/liv.12611] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
322 Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;31:679-692. [PMID: 20415840 DOI: 10.1111/j.1365-2036.2009.04230.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 73] [Article Influence: 10.6] [Reference Citation Analysis]
323 Zsóri G, Illés D, Ivány E, Kosár K, Holzinger G, Tajti M, Pálinkás E, Szabovik G, Nagy A, Palkó A, Czakó L. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. Metab Syndr Relat Disord 2019;17:289-95. [PMID: 31013454 DOI: 10.1089/met.2018.0086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
324 Utzschneider KM, Bayer-Carter JL, Arbuckle MD, Tidwell JM, Richards TL, Craft S. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. Br J Nutr. 2013;109:1096-1104. [PMID: 22849970 DOI: 10.1017/s0007114512002966] [Cited by in Crossref: 50] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
325 Congiu M, Ryan MC, Desmond PV. No increase in the expression of key unfolded protein response genes in HCV genotype 3 patients with severe steatosis. Virus Res 2011;160:420-3. [PMID: 21741418 DOI: 10.1016/j.virusres.2011.06.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
326 Dai W, Zhang Z, Zhao S. The Risk of Type 2 Diabetes and Coronary Artery Disease in Non-obese Patients With Non-alcoholic Fatty Liver Disease: A Cohort Study. Front Cardiovasc Med 2021;8:680664. [PMID: 34490362 DOI: 10.3389/fcvm.2021.680664] [Reference Citation Analysis]
327 Trovato GM, Martines GF, Trovato FM, Pirri C, Pace P, Garozzo A, Castro A, Catalano D. Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance. Dig Dis Sci. 2012;57:535-544. [PMID: 21953137 DOI: 10.1007/s10620-011-1903-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
328 Mehta SR, Louise Thomas E, Patel N, Crofton ME, Mccarthy J, Eliahoo J, Morin SX, Fitzpatrick J, Durighel G, Goldstone AP, Johnston DG, Bell JD, Taylor-robinson SD. Proton magnetic resonance spectroscopy and ultrasound for hepatic fat quantification. Hepatology Research 2010;40:399-406. [DOI: 10.1111/j.1872-034x.2009.00620.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
329 Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019;76:1541-58. [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 33.7] [Reference Citation Analysis]
330 Hart CL, Batty GD, Morrison DS, Mitchell RJ, Smith GD. Obesity, overweight and liver disease in the Midspan prospective cohort studies. Int J Obes (Lond) 2010;34:1051-9. [PMID: 20142829 DOI: 10.1038/ijo.2010.20] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
331 Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36:1497-507. [PMID: 33217052 DOI: 10.1111/jgh.15353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
332 Gale C, Thomas EL, Jeffries S, Durighel G, Logan KM, Parkinson JR, Uthaya S, Santhakumaran S, Bell JD, Modi N. Adiposity and hepatic lipid in healthy full-term, breastfed, and formula-fed human infants: a prospective short-term longitudinal cohort study. Am J Clin Nutr 2014;99:1034-40. [PMID: 24572562 DOI: 10.3945/ajcn.113.080200] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
333 Tsang SWC, Ng WF, Wu BPY, Chow DA, Li ETH, Wong TC. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2006;21:116-21. [DOI: 10.1111/j.1440-1746.2005.04146.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
334 Asfari MM, Niyazi F, Lopez R, Dasarathy S, McCullough AJ. The association of nonalcoholic steatohepatitis and obstructive sleep apnea. Eur J Gastroenterol Hepatol 2017;29:1380-4. [PMID: 28914694 DOI: 10.1097/MEG.0000000000000973] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
335 Hall A, Covelli C, Manuguerra R, Luong TV, Buzzetti E, Tsochatzis E, Pinzani M, Dhillon AP. Transaminase abnormalities and adaptations of the liver lobule manifest at specific cut-offs of steatosis. Sci Rep 2017;7:40977. [PMID: 28106158 DOI: 10.1038/srep40977] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
336 Adams LA, Angulo P. Role of Liver Biopsy and Serum Markers of Liver Fibrosis in Non-alcoholic Fatty Liver Disease. Clinics in Liver Disease 2007;11:25-35. [DOI: 10.1016/j.cld.2007.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
337 Leite NC, Salles GF, Cardoso CR, Villela-Nogueira CA. Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis. Hepatol Res 2013;43:508-15. [PMID: 23067270 DOI: 10.1111/j.1872-034X.2012.01106.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
338 Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology 2005;22:330-8. [DOI: 10.1053/j.semdp.2006.04.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.4] [Reference Citation Analysis]
339 Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429-436. [PMID: 21987293 DOI: 10.1002/hep.24731] [Cited by in Crossref: 198] [Cited by in F6Publishing: 169] [Article Influence: 18.0] [Reference Citation Analysis]
340 Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, Fukui M, Nagata C, Takeda J. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol 2012; 18(13): 1508-1516 [PMID: 22509083 DOI: 10.3748/wjg.v18.i13.1508] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
341 Chang BH, Li L, Saha P, Chan L. Absence of adipose differentiation related protein upregulates hepatic VLDL secretion, relieves hepatosteatosis, and improves whole body insulin resistance in leptin-deficient mice. J Lipid Res 2010;51:2132-42. [PMID: 20424269 DOI: 10.1194/jlr.M004515] [Cited by in Crossref: 57] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
342 van Herpen NA, Schrauwen-Hinderling VB. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav. 2008;94:231-241. [PMID: 18222498 DOI: 10.1016/j.physbeh.2007.11.049] [Cited by in Crossref: 304] [Cited by in F6Publishing: 287] [Article Influence: 20.3] [Reference Citation Analysis]
343 Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW, Chen YD, Rotter JI; Nonalcoholic Steatohepatitis Clinical Research Network. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology 2010; 139: 1567-1576, 1576.e1-1576. e6. [PMID: 20708005 DOI: 10.1053/j.gastro.2010.07.057] [Cited by in Crossref: 209] [Cited by in F6Publishing: 213] [Article Influence: 17.4] [Reference Citation Analysis]
344 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 122] [Article Influence: 28.4] [Reference Citation Analysis]
345 Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology. 2012;55:1738-1745. [PMID: 22213436 DOI: 10.1002/hep.25548] [Cited by in Crossref: 162] [Cited by in F6Publishing: 142] [Article Influence: 16.2] [Reference Citation Analysis]
346 Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8 Suppl 1:S4-S8. [PMID: 19381118 DOI: 10.1016/s1665-2681(19)31820-4] [Cited by in Crossref: 188] [Cited by in F6Publishing: 1] [Article Influence: 14.5] [Reference Citation Analysis]
347 Akki AS, Chung SM, Rudolph BJ, Ewart MR. Differential Diagnosis of a Patient with Lysosomal Acid Lipase Deficiency: A Case Report. Laboratory Medicine 2018;49:377-84. [DOI: 10.1093/labmed/lmy027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
348 Rabinowich L, Shibolet O. Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease. Biomed Res Int 2015;2015:168905. [PMID: 26273591 DOI: 10.1155/2015/168905] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
349 García-Compeán D, Jáquez-Quintana JO, González-González JA, Lavalle-González FJ, Villarreal-Pérez JZ, Maldonado-Garza HJ. [Diabetes in liver cirrhosis]. Gastroenterol Hepatol 2013;36:473-82. [PMID: 23628170 DOI: 10.1016/j.gastrohep.2013.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
350 Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology. 2007;133:1814-1820. [PMID: 18054554 DOI: 10.1053/j.gastro.207.08.077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
351 Popov VB, Lim JK. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol. 2015;3:230-238. [PMID: 26623270 DOI: 10.14218/jcth.2015.00019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
352 Samji NS, Snell PD, Singal AK, Satapathy SK. Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2020;16:66-72. [PMID: 32922753 DOI: 10.1002/cld.948] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
353 Speakman JR, Goran MI. Tissue-Specificity and Ethnic Diversity in Obesity-Related Risk of Cancer May Be Explained by Variability in Insulin Response and Insulin Signaling Pathways. Obesity 2010;18:1071-8. [DOI: 10.1038/oby.2010.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
354 Saab KR, Kendrick J, Yracheta JM, Lanaspa MA, Pollard M, Johnson RJ. New insights on the risk for cardiovascular disease in African Americans: the role of added sugars. J Am Soc Nephrol 2015;26:247-57. [PMID: 25090991 DOI: 10.1681/ASN.2014040393] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
355 Cuthbertson DJ, Weickert MO, Lythgoe D, Sprung VS, Dobson R, Shoajee-Moradie F, Umpleby M, Pfeiffer AF, Thomas EL, Bell JD. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol. 2014;171:561-569. [PMID: 25298375 DOI: 10.1530/eje-14-0112] [Cited by in Crossref: 75] [Cited by in F6Publishing: 37] [Article Influence: 10.7] [Reference Citation Analysis]
356 Newsome PN. Recurrence of nonalcoholic fatty liver disease after liver transplantation: it is common, but does it affect outcome? Liver Transpl 2010;16:420-2. [PMID: 20373452 DOI: 10.1002/lt.22038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
357 Navarro LA, Wree A, Povero D, Berk MP, Eguchi A, Ghosh S, Papouchado BG, Erzurum SC, Feldstein AE. Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis. J Hepatol. 2015;62:412-420. [PMID: 25234945 DOI: 10.1016/j.jhep.2014.09.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
358 Piemonte F, Petrini S, Gaeta LM, Tozzi G, Bertini E, Devito R, Boldrini R, Marcellini M, Ciacco E, Nobili V. Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2008;23:e457-64. [DOI: 10.1111/j.1440-1746.2007.05070.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
359 Han EN, Cheong ES, Lee JI, Kim MC, Byrne CD, Sung KC. Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study. Clin Hypertens 2015;21:22. [PMID: 26893932 DOI: 10.1186/s40885-015-0032-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
360 Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013;13:e7233. [PMID: 23885277 DOI: 10.5812/hepatmon.7233] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
361 Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28 Suppl 4:64-70. [PMID: 24251707 DOI: 10.1111/jgh.12271] [Cited by in Crossref: 117] [Cited by in F6Publishing: 107] [Article Influence: 14.6] [Reference Citation Analysis]
362 Hua MC, Huang JL, Hu CC, Yao TC, Lai MW. Including Fibroblast Growth Factor-21 in Combined Biomarker Panels Improves Predictions of Liver Steatosis Severity in Children. Front Pediatr. 2019;7:420. [PMID: 31750276 DOI: 10.3389/fped.2019.00420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
363 Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology. 2016;64:1969-1977. [PMID: 27301913 DOI: 10.1002/hep.28677] [Cited by in Crossref: 147] [Cited by in F6Publishing: 119] [Article Influence: 24.5] [Reference Citation Analysis]
364 Guichelaar MM, Gawrieh S, Olivier M, Viker K, Krishnan A, Sanderson S, Malinchoc M, Watt KD, Swain JM, Sarr M, Charlton MR. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity (Silver Spring) 2013;21:1935-41. [PMID: 23418085 DOI: 10.1002/oby.20327] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
365 Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ; Liver Forum Case Definitions Working Group. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 2018;67:2001-12. [PMID: 29059456 DOI: 10.1002/hep.29607] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 15.8] [Reference Citation Analysis]
366 Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, Zein NN, Feldstein AE. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32:297-302. [PMID: 22097893 DOI: 10.1111/j.1478-3231.2011.02639.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 141] [Article Influence: 12.3] [Reference Citation Analysis]
367 Adams LA, Knuiman MW, Divitini ML, Olynyk JK. Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumption. J Gastroenterol Hepatol 2008;23:1089-93. [PMID: 18557801 DOI: 10.1111/j.1440-1746.2008.05451.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
368 Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2121-30.e1-2. [PMID: 24846279 DOI: 10.1016/j.cgh.2014.05.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 8.1] [Reference Citation Analysis]
369 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
370 Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19-31. [PMID: 24274862 DOI: 10.1016/j.cld.2013.09.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
371 White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017;152:812-820.e5. [PMID: 27889576 DOI: 10.1053/j.gastro.2016.11.020] [Cited by in Crossref: 222] [Cited by in F6Publishing: 204] [Article Influence: 37.0] [Reference Citation Analysis]
372 Abbasalizad Farhangi M, Mohseni F, Farajnia S, Jafarabadi MA. Major components of metabolic syndrome and nutritional intakes in different genotype of UCP2 -866G/A gene polymorphisms in patients with NAFLD. J Transl Med 2016;14:177. [PMID: 27301474 DOI: 10.1186/s12967-016-0936-3] [Reference Citation Analysis]
373 Anderson SW, Soto JA, Milch HN, Ozonoff A, O'Brien M, Hamilton JA, Jara HJ. Effect of disease progression on liver apparent diffusion coefficient values in a murine model of NASH at 11.7 Tesla MRI. J Magn Reson Imaging 2011;33:882-8. [PMID: 21448953 DOI: 10.1002/jmri.22481] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
374 Ting YW, Kong AS, Zain SM, Chan WK, Tan HL, Mohamed Z, Pung YF, Mohamed R. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. Clin Mol Hepatol 2021;27:486-98. [PMID: 33618508 DOI: 10.3350/cmh.2020.0162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
375 Nyberg LM, Cheetham TC, Patton HM, Yang SJ, Chiang KM, Caparosa SL, Stern JA, Nyberg AH. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States. Hepatol Commun 2021;5:83-96. [PMID: 33437903 DOI: 10.1002/hep4.1625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
376 Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80-87. [PMID: 17187406 DOI: 10.1002/hep.21455] [Cited by in Crossref: 125] [Cited by in F6Publishing: 113] [Article Influence: 8.3] [Reference Citation Analysis]
377 Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. Clin Drug Investig. 2016;36:313-319. [PMID: 26914659 DOI: 10.1007/s40261-016-0383-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
378 Wollenman CS, Chason R, Reisch JS, Rockey DC. Impact of ethnicity in upper gastrointestinal hemorrhage. J Clin Gastroenterol 2014;48:343-50. [PMID: 24275716 DOI: 10.1097/MCG.0000000000000025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
379 Lindbäck SM, Gabbert C, Johnson BL, Smorodinsky E, Sirlin CB, Garcia N, Pardee PE, Kistler KD, Schwimmer JB. Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics 2010;57:85-140. [DOI: 10.1016/j.yapd.2010.08.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
380 Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, Yasells Garcia A, Del Rosario Abreu Vazquez M. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009;30:999-1009. [PMID: 19691668 DOI: 10.1111/j.1365-2036.2009.04122.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 5.2] [Reference Citation Analysis]
381 Schneider AL, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring). 2014;22:292-299. [PMID: 23512725 DOI: 10.1002/oby.20426] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 8.0] [Reference Citation Analysis]
382 Guo L, Guo YY, Li BY, Peng WQ, Chang XX, Gao X, Tang QQ. Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease. J Biol Chem 2019;294:11805-16. [PMID: 31197036 DOI: 10.1074/jbc.RA119.008708] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
383 Wang LF, Wang XN, Huang CC, Hu L, Xiao YF, Guan XH, Qian YS, Deng KY, Xin HB. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway. Lipids Health Dis 2017;16:82. [PMID: 28449683 DOI: 10.1186/s12944-017-0464-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
384 Valenti L, Dongiovanni P. Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach. Transl Res 2010;156:226-8. [PMID: 20875898 DOI: 10.1016/j.trsl.2010.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
385 Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. J Pediatr. 2011;158:740-744. [PMID: 21168155 DOI: 10.1016/j.jpeds.2010.11.016] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 5.0] [Reference Citation Analysis]
386 Brennan P, Clare K, George J, Dillon JF. Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review. World J Gastroenterol 2020; 26(15): 1683-1690 [PMID: 32351286 DOI: 10.3748/wjg.v26.i15.1683] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
387 Vuppalanchi R, Unalp A, Van Natta ML, Cummings OW, Sandrasegaran KE, Hameed T, Tonascia J, Chalasani N. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol 2009;7:481-6. [PMID: 19162235 DOI: 10.1016/j.cgh.2008.12.015] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 7.9] [Reference Citation Analysis]
388 Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510:84-91. [PMID: 24899308 DOI: 10.1038/nature13478] [Cited by in Crossref: 621] [Cited by in F6Publishing: 581] [Article Influence: 77.6] [Reference Citation Analysis]
389 Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112:18-35. [PMID: 27995906 DOI: 10.1038/ajg.2016.517] [Cited by in Crossref: 300] [Cited by in F6Publishing: 244] [Article Influence: 50.0] [Reference Citation Analysis]
390 Gawrieh S, Chalasani N. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:189-99. [PMID: 29128056 DOI: 10.1016/j.cld.2017.08.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
391 Zaki M, Kamal S, Kholousi S, El-Bassyouni HT, Yousef W, Reyad H, Mohamed R, Basha WA. Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in Egyptian obese women. EXCLI J 2017;16:973-80. [PMID: 28900377 DOI: 10.17179/excli2017-275] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
392 Hu J, Xu Y, He Z, Zhang H, Lian X, Zhu T, Liang C, Li J. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget. 2017;9:2752-2760. [PMID: 29416808 DOI: 10.18632/oncotarget.22755] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
393 Turola E, Petta S, Vanni E, Milosa F, Valenti L, Critelli R, Miele L, Maccio L, Calvaruso V, Fracanzani AL. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. Dis Model Mech. 2015;8:1037-1046. [PMID: 26183212 DOI: 10.1242/dmm.019950] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
394 Caballería L, Pera G, Auladell MA, Torán P, Muñoz L, Miranda D, Alumà A, Casas JD, Sánchez C, Gil D, Aubà J, Tibau A, Canut S, Bernad J, Aizpurua MM. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. European Journal of Gastroenterology & Hepatology 2010;22:24-32. [DOI: 10.1097/meg.0b013e32832fcdf0] [Cited by in Crossref: 123] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
395 Jozefczuk J, Kashofer K, Ummanni R, Henjes F, Rehman S, Geenen S, Wruck W, Regenbrecht C, Daskalaki A, Wierling C, Turano P, Bertini I, Korf U, Zatloukal K, Westerhoff HV, Lehrach H, Adjaye J. A Systems Biology Approach to Deciphering the Etiology of Steatosis Employing Patient-Derived Dermal Fibroblasts and iPS Cells. Front Physiol. 2012;3:339. [PMID: 22969728 DOI: 10.3389/fphys.2012.00339] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
396 Hahn L, Reeder SB, Muñoz del Rio A, Pickhardt PJ. Longitudinal Changes in Liver Fat Content in Asymptomatic Adults: Hepatic Attenuation on Unenhanced CT as an Imaging Biomarker for Steatosis. AJR Am J Roentgenol 2015;205:1167-72. [PMID: 26587921 DOI: 10.2214/AJR.15.14724] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
397 Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240:809-820. [PMID: 25873078 DOI: 10.1177/1535370215579161] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 8.1] [Reference Citation Analysis]
398 Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, Chim AM, Shen J, Ho CS, Woo J. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol. 2014;109:589-597. [PMID: 24492753 DOI: 10.1038/ajg.2014.1] [Cited by in Crossref: 117] [Cited by in F6Publishing: 115] [Article Influence: 14.6] [Reference Citation Analysis]
399 Carabelli J, Burgueño AL, Rosselli MS, Gianotti TF, Lago NR, Pirola CJ, Sookoian S. High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. J Cell Mol Med 2011;15:1329-38. [PMID: 20629985 DOI: 10.1111/j.1582-4934.2010.01128.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 5.5] [Reference Citation Analysis]
400 Bohinc BN, Diehl AM. Mechanisms of disease progression in NASH: new paradigms. Clin Liver Dis. 2012;16:549-565. [PMID: 22824480 DOI: 10.1016/j.cld.2012.05.002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
401 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 288] [Article Influence: 43.1] [Reference Citation Analysis]
402 Goedeke L, Bates J, Vatner DF, Perry RJ, Wang T, Ramirez R, Li L, Ellis MW, Zhang D, Wong KE, Beysen C, Cline GW, Ray AS, Shulman GI. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents. Hepatology. 2018;68:2197-2211. [PMID: 29790582 DOI: 10.1002/hep.30097] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 29.7] [Reference Citation Analysis]
403 Ress C, Kaser S. Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol 2016; 22(4): 1664-1673 [PMID: 26819531 DOI: 10.3748/wjg.v22.i4.1664] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
404 Paul J, Venugopal RV, Peter L, Shetty KNK, Shetti MP. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY. Arq Gastroenterol 2018;55:7-13. [DOI: 10.1590/s0004-2803.201800000-07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
405 Tanajewski L, Harris R, Harman DJ, Aithal GP, Card TR, Gkountouras G, Berdunov V, Guha IN, Elliott RA. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open. 2017;7:e015659. [PMID: 28679676 DOI: 10.1136/bmjopen-2016-015659] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
406 Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, Borén J, Montalcini T, Pujia A, Wiklund O, Hindy G, Spagnuolo R, Motta BM, Pipitone RM, Craxì A, Fargion S, Nobili V, Käkelä P, Kärjä V, Männistö V, Pihlajamäki J, Reilly DF, Castro-Perez J, Kozlitina J, Valenti L, Romeo S. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology 2016;150:1219-1230.e6. [PMID: 26850495 DOI: 10.1053/j.gastro.2016.01.032] [Cited by in Crossref: 285] [Cited by in F6Publishing: 280] [Article Influence: 47.5] [Reference Citation Analysis]
407 Chang E, Park CY, Park SW. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig 2013;4:517-24. [PMID: 24843703 DOI: 10.1111/jdi.12107] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
408 Smagris E, Gilyard S, BasuRay S, Cohen JC, Hobbs HH. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins. J Biol Chem. 2016;291:10659-10676. [PMID: 27013658 DOI: 10.1074/jbc.m116.719955] [Cited by in Crossref: 106] [Cited by in F6Publishing: 69] [Article Influence: 17.7] [Reference Citation Analysis]
409 Parente DB, Rodrigues RS, Paiva FF, Oliveira Neto JA, Machado-Silva L, Lanzoni V, Campos CF, Eiras-Araujo AL, do Brasil PE, Garteiser P, Gomes MB, de Mello Perez R. Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? PLoS One 2014;9:e112574. [PMID: 25426708 DOI: 10.1371/journal.pone.0112574] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
410 Balas B, Belfort R, Harrison SA, Darland C, Finch J, Schenker S, Gastaldelli A, Cusi K. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol. 2007;47:565-570. [PMID: 17560678 DOI: 10.1016/j.jhep.2007.04.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
411 Eckard AR, Hughes HY, Hagood NL, O'Riordan MA, Labbato D, Kosco JC, Scott SE, McComsey GA. Fibroblast Growth Factor 21 Is Elevated in HIV and Associated With Interleukin-6. J Acquir Immune Defic Syndr 2020;83:e30-3. [PMID: 31913998 DOI: 10.1097/QAI.0000000000002285] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
412 Cho JY, Jeong JY, Sohn W. Risk of metabolic syndrome in participants within the normal range of alanine aminotransferase: A population-based nationwide study. PLoS One 2020;15:e0231485. [PMID: 32267895 DOI: 10.1371/journal.pone.0231485] [Reference Citation Analysis]
413 Shao C, Ye J, Li F, Feng S, Wang W, Zhong B. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Digestive and Liver Disease 2019;51:1392-9. [DOI: 10.1016/j.dld.2019.02.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
414 Liu W, Anstee QM, Wang X, Gawrieh S, Gamazon ER, Athinarayanan S, Liu YL, Darlay R, Cordell HJ, Daly AK, Day CP, Chalasani N. Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. Aging (Albany NY) 2016;9:26-40. [PMID: 27744419 DOI: 10.18632/aging.101067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
415 Attie AD, Scherer PE. Adipocyte metabolism and obesity. J Lipid Res. 2009;50 Suppl:S395-S399. [PMID: 19017614 DOI: 10.1194/jlr.r800057-jlr200] [Cited by in Crossref: 132] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
416 Díaz-rúa R, van Schothorst EM, Keijer J, Palou A, Oliver P. Isocaloric high-fat feeding directs hepatic metabolism to handling of nutrient imbalance promoting liver fat deposition. Int J Obes 2016;40:1250-9. [DOI: 10.1038/ijo.2016.47] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
417 Cheung O, Kapoor A, Puri P, Sistrun S, Luketic VA, Sargeant CC, Contos MJ, Shiffman ML, Stravitz RT, Sterling RK. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology. 2007;46:1091-1100. [PMID: 17610277 DOI: 10.1002/hep.21803] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 5.2] [Reference Citation Analysis]
418 Razonable RR, Findlay JY, O’Riordan A, Burroughs SG, Ghobrial RM, Agarwal B, Davenport A, Gropper M. Critical care issues in patients after liver transplantation. Liver Transpl. 2011;17:511-527. [PMID: 21384524 DOI: 10.1002/lt.22291] [Cited by in Crossref: 69] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
419 Sinn DH, Gwak GY, Park HN, Kim JE, Min YW, Kim KM, Kim YJ, Choi MS, Lee JH, Koh KC. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol. 2012;107:561-567. [PMID: 22108448 DOI: 10.1038/ajg.2011.400] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 6.6] [Reference Citation Analysis]
420 Akinkugbe AA, Barritt AS, Cai J, Offenbacher S, Thyagarajan B, Khambaty T, Singer R, Kallwitz E, Heiss G, Slade GD. Periodontitis and prevalence of elevated aminotransferases in the Hispanic Community Health Study/Study of Latinos. J Periodontol 2018;89:949-58. [PMID: 29717494 DOI: 10.1002/JPER.17-0579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
421 Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, Duvillard L, Denimal D, Loffroy R, Vergès B, Hillon P, Petit JM. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. Diabet Med 2018;35:368-75. [PMID: 29247558 DOI: 10.1111/dme.13565] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
422 Scorletti E, Calder PC, Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 2011;40:332-43. [DOI: 10.1007/s12020-011-9530-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
423 Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013; 19(41): 6969-6978 [PMID: 24222941 DOI: 10.3748/wjg.v19.i41.6969] [Cited by in CrossRef: 139] [Cited by in F6Publishing: 129] [Article Influence: 15.4] [Reference Citation Analysis]
424 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
425 Karanjia RN, Crossey MME, Cox IJ, Fye HKS, Njie R, Goldin RD, Taylor-Robinson SD. Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol 2016; 22(45): 9880-9897 [PMID: 28018096 DOI: 10.3748/wjg.v22.i45.9880] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
426 Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854. [PMID: 17393509 DOI: 10.1002/hep.21496] [Cited by in Crossref: 1507] [Cited by in F6Publishing: 1351] [Article Influence: 100.5] [Reference Citation Analysis]
427 Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82:315-22. [PMID: 16679470 DOI: 10.1136/pgmj.2005.042200] [Cited by in Crossref: 165] [Cited by in F6Publishing: 148] [Article Influence: 10.3] [Reference Citation Analysis]
428 Nasr P, Hilliges A, Thorelius L, Kechagias S, Ekstedt M. Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology 2016;51:1126-32. [DOI: 10.3109/00365521.2016.1172336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
429 Xiao J, Guo R, Fung ML, Liong EC, Tipoe GL. Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary Pancreat Dis Int. 2013;12:125-135. [PMID: 23558065 DOI: 10.1016/s1499-3872(13)60021-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
430 Petäjä EM, Sevastianova K, Hakkarainen A, Orho-melander M, Lundbom N, Yki-järvinen H. Adipocyte size is associated with NAFLD independent of obesity, fat distribution, and PNPLA3 genotype: Adipocyte Size, Liver Fat. Obesity 2013;21:1174-9. [DOI: 10.1002/oby.20114] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
431 Browning JD, Cohen JC, Hobbs HH. Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology 2010;52:1189-92. [PMID: 20879029 DOI: 10.1002/hep.23946] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
432 Leopold C, Duta-Mare M, Sachdev V, Goeritzer M, Maresch LK, Kolb D, Reicher H, Wagner B, Stojakovic T, Ruelicke T, Haemmerle G, Hoefler G, Sattler W, Kratky D. Hepatocyte-specific lysosomal acid lipase deficiency protects mice from diet-induced obesity but promotes hepatic inflammation. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:500-511. [PMID: 30639734 DOI: 10.1016/j.bbalip.2019.01.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
433 Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13(10): 1579-1584 [PMID: 17461452 DOI: 10.3748/wjg.v13.i10.1579] [Cited by in CrossRef: 346] [Cited by in F6Publishing: 335] [Article Influence: 23.1] [Reference Citation Analysis]
434 Bril F, Cusi K. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. Endocrinol Metab Clin North Am 2016;45:765-81. [PMID: 27823604 DOI: 10.1016/j.ecl.2016.06.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 10.8] [Reference Citation Analysis]
435 Stender S, Kozlitina J, Nordestgaard BG, Tybjærg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 2017;49:842-7. [PMID: 28436986 DOI: 10.1038/ng.3855] [Cited by in Crossref: 147] [Cited by in F6Publishing: 142] [Article Influence: 29.4] [Reference Citation Analysis]
436 Li Y, Xiong F, Xu W, Liu S. Increased Serum Angiotensin II Is a Risk Factor of Nonalcoholic Fatty Liver Disease: A Prospective Pilot Study. Gastroenterol Res Pract 2019;2019:5647161. [PMID: 31827504 DOI: 10.1155/2019/5647161] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
437 Lu J, Zhang J, Du R, Wang T, Xu M, Xu Y, Wang W, Bi Y, Li D, Chen Y, Ning G. Age at menarche is associated with the prevalence of non-alcoholic fatty liver disease later in life. J Diabetes 2017;9:53-60. [PMID: 26800495 DOI: 10.1111/1753-0407.12379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
438 Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, Gupta N, Cotler SJ. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci. 2008;53:1358-1363. [PMID: 18347982 DOI: 10.1007/s10620-008-0234-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
439 Shi ZH, Lin LL, Feng YX, Zheng YQ. Fistular onion stalk extract reduces NF-κB expression and TNF-α secretion in steatotic HepG2 cells. Shijie Huaren Xiaohua Zazhi 2010; 18(32): 3457-3461 [DOI: 10.11569/wcjd.v18.i32.3457] [Reference Citation Analysis]
440 Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180-190. [PMID: 27646933 DOI: 10.1136/gutjnl-2016-312431] [Cited by in Crossref: 214] [Cited by in F6Publishing: 213] [Article Influence: 35.7] [Reference Citation Analysis]
441 Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:145-155. [PMID: 25755423 DOI: 10.1016/s0973-6883(12)60103-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
442 Meroni M, Longo M, Dongiovanni P. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine 2020;1:218-43. [DOI: 10.37349/emed.2020.00015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Hobbs HH. Science, serendipity, and the single degree. J Clin Invest 2018;128:4218-23. [PMID: 30272579 DOI: 10.1172/JCI124404] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
444 Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56:952-964. [PMID: 22173168 DOI: 10.1016/j.jhep.2011.08.025] [Cited by in Crossref: 452] [Cited by in F6Publishing: 440] [Article Influence: 41.1] [Reference Citation Analysis]
445 Utzschneider KM, Kahn SE. The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism 2006;91:4753-61. [DOI: 10.1210/jc.2006-0587] [Cited by in Crossref: 476] [Cited by in F6Publishing: 451] [Article Influence: 29.8] [Reference Citation Analysis]
446 Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20. [PMID: 28930295 DOI: 10.1038/nrgastro.2017.109] [Cited by in Crossref: 1421] [Cited by in F6Publishing: 1332] [Article Influence: 284.2] [Reference Citation Analysis]
447 Kim H, Lee K, Lee KW, Yi NJ, Lee HW, Hong G, Choi Y, You T, Suh SW, Jang JJ. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant. 2014;28:521-529. [PMID: 24579874 DOI: 10.1111/ctr.12343] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
448 Hennig EE, Mikula M, Goryca K, Paziewska A, Ledwon J, Nesteruk M, Woszczynski M, Walewska-Zielecka B, Pysniak K, Ostrowski J. Extracellular matrix and cytochrome P450 gene expression can distinguish steatohepatitis from steatosis in mice. J Cell Mol Med 2014;18:1762-72. [PMID: 24913135 DOI: 10.1111/jcmm.12328] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
449 Bhati C, Idowu MO, Sanyal AJ, Rivera M, Driscoll C, Stravitz RT, Kohli DR, Matherly S, Puri P, Gilles H, Cotterell A, Levy M, Sterling RK, Luketic VA, Lee H, Sharma A, Siddiqui MS. Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis. Transplantation. 2017;101:1867-1874. [PMID: 28296807 DOI: 10.1097/tp.0000000000001709] [Cited by in Crossref: 65] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
450 Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, Roddy T, Castro-Perez J, Cohen JC, Hobbs HH. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest. 2012;122:4130-4144. [PMID: 23023705 DOI: 10.1172/jci65179] [Cited by in Crossref: 166] [Cited by in F6Publishing: 99] [Article Influence: 18.4] [Reference Citation Analysis]
451 Yang Z, Wen J, Tao X, Lu B, Du Y, Wang M, Wang X, Zhang W, Gong W, Ling C. Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Mol Biol Rep. 2011;38:1145-1150. [PMID: 20625834 DOI: 10.1007/s11033-010-0212-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
452 Nadelson J, Satapathy SK, Nair S. Glycated Hemoglobin Levels in Patients with Decompensated Cirrhosis. Int J Endocrinol. 2016;2016:8390210. [PMID: 27882051 DOI: 10.1155/2016/8390210] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
453 Tabibian JH, Lazo M, Durazo FA, Yeh HC, Tong MJ, Clark JM. Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? J Gastroenterol Hepatol. 2011;26:501-509. [PMID: 21332546 DOI: 10.1111/j.1440-1746.2010.06443.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
454 Friedman TC, Sinha-Hikim I, Parveen M, Najjar SM, Liu Y, Mangubat M, Shin CS, Lyzlov A, Ivey R, Shaheen M, French SW, Sinha-Hikim AP. Additive effects of nicotine and high-fat diet on hepatic steatosis in male mice. Endocrinology 2012;153:5809-20. [PMID: 23093702 DOI: 10.1210/en.2012-1750] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
455 Zeb I, Li D, Nasir K, Katz R, Larijani VN, Budoff MJ. Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis. Acad Radiol 2012;19:811-8. [PMID: 22521729 DOI: 10.1016/j.acra.2012.02.022] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 8.5] [Reference Citation Analysis]
456 Galloway CA, Yoon Y. Mitochondrial morphology in metabolic diseases. Antioxid Redox Signal. 2013;19:415-430. [PMID: 22793999 DOI: 10.1089/ars.2012.4779] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 6.9] [Reference Citation Analysis]
457 Guo L, Zhou SR, Wei XB, Liu Y, Chang XX, Liu Y, Ge X, Dou X, Huang HY, Qian SW, Li X, Lei QY, Gao X, Tang QQ. Acetylation of Mitochondrial Trifunctional Protein α-Subunit Enhances Its Stability To Promote Fatty Acid Oxidation and Is Decreased in Nonalcoholic Fatty Liver Disease. Mol Cell Biol 2016;36:2553-67. [PMID: 27457618 DOI: 10.1128/MCB.00227-16] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
458 Valenti L, Nobili V, Al-Serri A, Rametta R, Leathart JB, Zappa MA, Dongiovanni P, Fracanzani AL, Alterio A, Roviaro G. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol. 2011;55:1409-1414. [PMID: 21777557 DOI: 10.1016/j.jhep.2011.03.035] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
459 Ehman RL. Science to practice: can MR elastography be used to detect early steatohepatitis in fatty liver disease? Radiology. 2009;253:1-3. [PMID: 19789246 DOI: 10.1148/radiol.2531091040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
460 Shaheen M, Pan D, Schrode KM, Kermah D, Puri V, Zarrinpar A, Elisha D, Najjar SM, Friedman TC. Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics. Hepatol Commun 2021. [PMID: 34558824 DOI: 10.1002/hep4.1775] [Reference Citation Analysis]
461 Stowe KA, Burgess SC, Merritt M, Sherry AD, Malloy CR. Storage and oxidation of long-chain fatty acids in the C57/BL6 mouse heart as measured by NMR spectroscopy. FEBS Lett 2006;580:4282-7. [PMID: 16831433 DOI: 10.1016/j.febslet.2006.06.068] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
462 Meex RC, Hoy AJ, Morris A, Brown RD, Lo JC, Burke M, Goode RJ, Kingwell BA, Kraakman MJ, Febbraio MA. Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metab. 2015;22:1078-1089. [PMID: 26603189 DOI: 10.1016/j.cmet.2015.09.023] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 16.0] [Reference Citation Analysis]
463 Swain M, Nath P, Parida PK, Narayan J, Padhi PK, Pati GK, Singh A, Misra B, Misra D, Kar SK, Panigrahi MK, Meher C, Agrawal O, Rout N, Pattnaik K, Bhuyan P, Mishra PK, Singh SP. Biochemical Profile of Nonalcoholic Fatty Liver Disease Patients in Eastern India with Histopathological Correlation. Indian J Clin Biochem 2017;32:306-14. [PMID: 28811690 DOI: 10.1007/s12291-016-0612-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
464 Parsi A, Torkashvand M, Hajiani E, Rahimlou M, Sadeghi N. The effects of crocus sativus extract on serum lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: A randomized placebo-controlled study. Obesity Medicine 2020;17:100165. [DOI: 10.1016/j.obmed.2019.100165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
465 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
466 Fabbrini E, Cella M, McCartney SA, Fuchs A, Abumrad NA, Pietka TA, Chen Z, Finck BN, Han DH, Magkos F. Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology. 2013;145:366-374.e1-3. [PMID: 23597726 DOI: 10.1053/j.gastro.2013.04.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
467 Brouwers B, Schrauwen-hinderling V, Jelenik T, Gemmink A, Havekes B, Bruls Y, Dahlmans D, Roden M, Hesselink M, Schrauwen P. Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. Clinical Science 2017;131:1905-17. [DOI: 10.1042/cs20170261] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 4.4] [Reference Citation Analysis]
468 Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13(26): 3540-3553 [PMID: 17659704 DOI: 10.3748/wjg.v13.i26.3540] [Cited by in CrossRef: 160] [Cited by in F6Publishing: 148] [Article Influence: 10.7] [Reference Citation Analysis]
469 Calanna S, Scicali R, Di Pino A, Knop F, Piro S, Rabuazzo A, Purrello F. Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2014;24:670-6. [DOI: 10.1016/j.numecd.2014.01.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
470 Han J, He Y, Zhao H, Xu X. Hypoxia inducible factor-1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN/p65 signaling pathway. J Cell Biochem. 2019;120:14735-14744. [PMID: 31009107 DOI: 10.1002/jcb.28734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
471 Koh ZJ, Salgaonkar HP, Lee WJJ, Kim GW, Tan CH, Cheng A, Lomanto D, So JBY, Dan YY, Shabbir A. Improvement in Non-alcoholic Fatty Liver Disease Score Correlates with Weight Loss in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy: a Two-Centre Study from an Asian Cohort. Obes Surg 2019;29:862-8. [PMID: 30515622 DOI: 10.1007/s11695-018-3581-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
472 Zhao L, Zhong S, Qu H, Xie Y, Cao Z, Li Q, Yang P, Varghese Z, Moorhead JF, Chen Y, Ruan XZ. Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice. Sci Rep 2015;5:10222. [PMID: 25974206 DOI: 10.1038/srep10222] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
473 Kim G, Lee SE, Lee YB, Jun JE, Ahn J, Bae JC, Jin SM, Hur KY, Jee JH, Lee MK, Kim JH. Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study. Hepatology 2018;68:1755-68. [PMID: 29679374 DOI: 10.1002/hep.30049] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 14.0] [Reference Citation Analysis]
474 Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander M, Yki-Järvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009;137:865-72. [PMID: 19524579 DOI: 10.1053/j.gastro.2009.06.005] [Cited by in Crossref: 407] [Cited by in F6Publishing: 386] [Article Influence: 31.3] [Reference Citation Analysis]
475 Deng YY, Zhong QW, Zhong HL, Xiong F, Ke YB, Chen YM. Higher Healthy Lifestyle Score is associated with lower presence of non-alcoholic fatty liver disease in middle-aged and older Chinese adults: a community-based cross-sectional study. Public Health Nutr 2021;:1-9. [PMID: 33634772 DOI: 10.1017/S1368980021000902] [Reference Citation Analysis]
476 Carter-Kent C, Feldstein AE. Non-alcoholic steatohepatitis over multiple generations. Dig Dis Sci 2010;55:1494-7. [PMID: 19629685 DOI: 10.1007/s10620-009-0896-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
477 Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, Cavallo MG. Strong association between nonalcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011;9:85. [PMID: 21749681 DOI: 10.1186/1741-7015-9-85] [Cited by in Crossref: 187] [Cited by in F6Publishing: 169] [Article Influence: 17.0] [Reference Citation Analysis]
478 Serviddio G, Bellanti F, Vendemiale G. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic Biol Med. 2013;65:952-968. [PMID: 23994574 DOI: 10.1016/j.freeradbiomed.2013.08.174] [Cited by in Crossref: 133] [Cited by in F6Publishing: 120] [Article Influence: 14.8] [Reference Citation Analysis]
479 Zhou K, Dodge JL, Yuan L, Terrault NA. Metabolic Risk Profiles for Hepatic Steatosis Differ by Race/Ethnicity: An Elastography-Based Study of US Adults. Dig Dis Sci 2021. [PMID: 34173916 DOI: 10.1007/s10620-021-07124-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
480 Jiang ZG, Tapper EB. Cost Saving or Cost Effective? Unanswered Questions in the Screening of Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:1293-5. [PMID: 31592491 DOI: 10.1002/hep4.1386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
481 Akhlaghi M, Ghasemi-Nasab M, Riasatian M. Mediterranean diet for patients with non-alcoholic fatty liver disease, a systematic review and meta-analysis of observational and clinical investigations. J Diabetes Metab Disord 2020;19:575-84. [PMID: 32550210 DOI: 10.1007/s40200-019-00475-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
482 Chleilat F, Schick A, Reimer RA. Microbiota Changes in Fathers Consuming a High Prebiotic Fiber Diet Have Minimal Effects on Male and Female Offspring in Rats. Nutrients 2021;13:820. [PMID: 33801321 DOI: 10.3390/nu13030820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
483 Caravatto PP, Cohen R. The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement. Curr Atheroscler Rep. 2017;19:45. [PMID: 28986720 DOI: 10.1007/s11883-017-0681-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
484 Robbins AJ, Ritter S, Markese M, Skube ME, McEachron KR, Bellin MD, Stice MJ, Beilman GJ, Schat R, Spilseth B. Atypical Hepatic Steatosis Patterns on MRI After Total Pancreatectomy With Islet Autotransplant. AJR Am J Roentgenol 2021;217:100-6. [PMID: 33909467 DOI: 10.2214/AJR.20.23303] [Reference Citation Analysis]
485 Ruffillo G, Fassio E, Alvarez E, Landeira G, Longo C, Domínguez N, Gualano G. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. Journal of Hepatology 2011;54:160-3. [DOI: 10.1016/j.jhep.2010.06.028] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
486 Videla LA, Pettinelli P. Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. PPAR Res. 2012;2012:107434. [PMID: 23304111 DOI: 10.1155/2012/107434] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
487 Fan L, Fu Z, Xiong Y, Ye S, Wang Y, Peng G, Ye Q. Double-lobectomy in a steatotic liver transplantation rat model. Exp Ther Med 2021;21:256. [PMID: 33603863 DOI: 10.3892/etm.2021.9687] [Reference Citation Analysis]
488 Liu CQ, He CM, Chen N, Wang D, Shi X, Liu Y, Zeng X, Yan B, Liu S, Yang S, Li X, Li X, Li Z. Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults. Sci Rep. 2016;6:38605. [PMID: 27924915 DOI: 10.1038/srep38605] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
489 Mcpherson S, Anstee QM. Changing epidemiology of chronic liver disease among ethnic groups in the United States: McPherson and Anstee. Hepatology 2016;64:1843-6. [DOI: 10.1002/hep.28783] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
490 Link JC, Reue K. Genetic Basis for Sex Differences in Obesity and Lipid Metabolism. Annu Rev Nutr 2017;37:225-45. [PMID: 28628359 DOI: 10.1146/annurev-nutr-071816-064827] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 19.4] [Reference Citation Analysis]
491 Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW;  Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-1144. [PMID: 21478462 DOI: 10.2337/dc10-2229] [Cited by in Crossref: 217] [Cited by in F6Publishing: 202] [Article Influence: 19.7] [Reference Citation Analysis]
492 Ma Y, Brown PM, Lin DD, Ma J, Feng D, Belyaeva OV, Podszun MC, Roszik J, Allen JN, Umarova R, Kleiner DE, Kedishvili NY, Gavrilova O, Gao B, Rotman Y. 17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury. Hepatology 2021;73:1701-16. [PMID: 32779242 DOI: 10.1002/hep.31517] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
493 Abdelmalek MF, Diehl AM. Mechanisms underlying nonalcoholic steatohepatitis. Drug Discovery Today: Disease Mechanisms 2006;3:479-88. [DOI: 10.1016/j.ddmec.2006.11.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
494 Rudolph B, Bjorklund N, Ovchinsky N, Kogan-Liberman D, Perez A, Liszewski M, Levin TL, Ewart M, Liu Q, Xue X, Viswanathan S, Strickler HD. Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design. Contemp Clin Trials 2018;75:51-8. [PMID: 30401631 DOI: 10.1016/j.cct.2018.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
495 Wilman HR, Kelly M, Garratt S, Matthews PM, Milanesi M, Herlihy A, Gyngell M, Neubauer S, Bell JD, Banerjee R, Thomas EL. Characterisation of liver fat in the UK Biobank cohort. PLoS One. 2017;12:e0172921. [PMID: 28241076 DOI: 10.1371/journal.pone.0172921] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 8.4] [Reference Citation Analysis]
496 Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95:314-322. [PMID: 31085617 DOI: 10.1136/postgradmedj-2018-136316] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
497 Hong Y, Dufendach K, Wang Y, Thoma F, Kilic A. Impact of hepatic steatosis on outcomes after left ventricular assist device implantation. J Card Surg 2021;36:2277-83. [PMID: 33783048 DOI: 10.1111/jocs.15536] [Reference Citation Analysis]
498 Spahis S, Delvin E, Borys JM, Levy E. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. Antioxid Redox Signal. 2017;26:519-541. [PMID: 27452109 DOI: 10.1089/ars.2016.6776] [Cited by in Crossref: 173] [Cited by in F6Publishing: 163] [Article Influence: 28.8] [Reference Citation Analysis]
499 Sawaf B, Ali AH, Jaafar RF, Kanso M, Mukherji D, Khalife MJ, Faraj W. Spectrum of liver diseases in patients referred for Fibroscan: A single center experience in the Middle East. Ann Med Surg (Lond) 2020;57:166-70. [PMID: 32774848 DOI: 10.1016/j.amsu.2020.07.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
500 Fargion S, Valenti L, Fracanzani AL. Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Dig Liver Dis. 2011;43:89-95. [PMID: 20739232 DOI: 10.1016/j.dld.2010.07.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
501 Guzmán Aroca F, Ayala I, Serrano L, Berná-Serna JD, Castell MT, García-Pérez B, Reus M. Assessment of liver steatosis in chicken by using acoustic radiation force impulse imaging: preliminary results. Eur Radiol 2010;20:2367-71. [PMID: 20445981 DOI: 10.1007/s00330-010-1808-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
502 Mayer C, Richard L, Côme M, Ulmann L, Nazih H, Chénais B, Ouguerram K, Mimouni V. The Marine Microalga, Tisochrysis lutea, Protects against Metabolic Disorders Associated with Metabolic Syndrome and Obesity. Nutrients 2021;13:430. [PMID: 33525643 DOI: 10.3390/nu13020430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
503 Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol. 2012;57:1305-1311. [PMID: 22871499 DOI: 10.1016/j.jhep.2012.07.028] [Cited by in Crossref: 135] [Cited by in F6Publishing: 115] [Article Influence: 13.5] [Reference Citation Analysis]
504 Trunečka P, Míková I, Dlouhá D, Hubáček JA, Honsová E, Kolesár L, Lánská V, Fraňková S, Šperl J, Jirsa M, Poledne R. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. Dig Liver Dis 2018;50:490-5. [PMID: 29396131 DOI: 10.1016/j.dld.2017.12.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
505 Milroy CM. Fatty Liver and the Forensic Pathologist. Acad Forensic Pathol 2018;8:296-310. [PMID: 31240043 DOI: 10.1177/1925362118782061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
506 Walker RW, Belbin GM, Sorokin EP, Van Vleck T, Wojcik GL, Moscati A, Gignoux CR, Cho J, Abul-Husn NS, Nadkarni G, Kenny EE, Loos RJF. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J Hepatol 2020;72:1070-81. [PMID: 32145261 DOI: 10.1016/j.jhep.2020.01.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
507 Rotman Y, Neuschwander-Tetri BA. Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. Hepatology 2017;65:1088-90. [PMID: 28152575 DOI: 10.1002/hep.29094] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
508 Davidson LE, Kuk JL, Church TS, Ross R. Protocol for measurement of liver fat by computed tomography. J Appl Physiol (1985) 2006;100:864-8. [PMID: 16293702 DOI: 10.1152/japplphysiol.00986.2005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 2.6] [Reference Citation Analysis]
509 Winters SJ, Scoggins CR, Appiah D, Ghooray DT. The hepatic lipidome and HNF4α and SHBG expression in human liver. Endocr Connect 2020;9:1009-18. [PMID: 33064664 DOI: 10.1530/EC-20-0401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
510 Yun JW, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI. Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int 2009;29:525-9. [PMID: 19323780 DOI: 10.1111/j.1478-3231.2008.01920.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
511 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
512 M. Brunt E, G. Tiniakos D. Fatty Liver Disease. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Elsevier; 2009. pp. 1087-114. [DOI: 10.1016/b978-141604059-0.50044-8] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
513 Almeda-valdes P, Aguilar-salinas CA, Uribe M, Canizales-quinteros S, Méndez-sánchez N. Impact of anthropometric cut-off values in determining the prevalence of metabolic alterations. Eur J Clin Invest 2016;46:940-6. [DOI: 10.1111/eci.12672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
514 Roulot D, Roudot-thoraval F, Nkontchou G, Kouacou N, Costes J, Elourimi G, Le Clesiau H, Ziol M, Beaugrand M. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan. Liver Int 2017;37:1897-906. [DOI: 10.1111/liv.13481] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
515 Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol 2014; 6(5): 274-283 [PMID: 24868321 DOI: 10.4254/wjh.v6.i5.274] [Cited by in Crossref: 160] [Cited by in F6Publishing: 146] [Article Influence: 20.0] [Reference Citation Analysis]
516 Khosravi-Boroujeni H, Ahmed F, Sadeghi M, Roohafza H, Talaei M, Dianatkhah M, Pourmogaddas A, Sarrafzadegan N. Does the impact of metabolic syndrome on cardiovascular events vary by using different definitions? BMC Public Health 2015;15:1313. [PMID: 26715355 DOI: 10.1186/s12889-015-2623-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
517 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
518 Forcheron F, Abdallah P, Basset A, del Carmine P, Haffar G, Beylot M. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. Obesity (Silver Spring). 2009;17:1381-1389. [PMID: 19553925 DOI: 10.1038/oby.2008.661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
519 van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis. 2008;12:805-824, ix. [PMID: 18984468 DOI: 10.1016/j.cld.2008.07.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
520 Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, Yan QW, Miyoshi H, Mashek DG. The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest 2011;121:2102-10. [PMID: 21633178 DOI: 10.1172/JCI46069] [Cited by in Crossref: 396] [Cited by in F6Publishing: 231] [Article Influence: 36.0] [Reference Citation Analysis]
521 Oladunjoye O, Oladunjoye AO, Dhital R, Poudel D, Oladiran OD, Oke IO, Areoye G, Jehangir A, Shogbesan O. A Retrospective Study of Hospitalizations in the USA: Proportion of Hospitalizations With Non-Alcoholic Fatty Liver Disease in Non-Obese Population. Cureus 2021;13:e17869. [PMID: 34660070 DOI: 10.7759/cureus.17869] [Reference Citation Analysis]
522 Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, McCullough AJ. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015;49:137-44. [PMID: 24583757 DOI: 10.1097/MCG.0000000000000099] [Cited by in Crossref: 99] [Cited by in F6Publishing: 47] [Article Influence: 14.1] [Reference Citation Analysis]
523 Browning JD, Weis B, Davis J, Satapati S, Merritt M, Malloy CR, Burgess SC. Alterations in hepatic glucose and energy metabolism as a result of calorie and carbohydrate restriction. Hepatology 2008;48:1487-96. [PMID: 18925642 DOI: 10.1002/hep.22504] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
524 Jiao J, Watt GP, Lee M, Rahbar MH, Vatcheva KP, Pan JJ, McCormick JB, Fisher-Hoch SP, Fallon MB, Beretta L. Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity. PLoS One 2016;11:e0150978. [PMID: 26950933 DOI: 10.1371/journal.pone.0150978] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
525 Brachs S, Winkel AF, Tang H, Birkenfeld AL, Brunner B, Jahn-Hofmann K, Margerie D, Ruetten H, Schmoll D, Spranger J. Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice. Mol Metab 2016;5:1072-82. [PMID: 27818933 DOI: 10.1016/j.molmet.2016.08.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
526 Katzmarzyk PT, Shen W, Baxter-jones A, Bell JD, Butte NF, Demerath EW, Gilsanz V, Goran MI, Hirschler V, Hu HH, Maffeis C, Malina RM, Müller MJ, Pietrobelli A, Wells JCK. Adiposity in children and adolescents: correlates and clinical consequences of fat stored in specific body depots: Correlates and consequences of obesity. Pediatric Obesity 2012;7:e42-61. [DOI: 10.1111/j.2047-6310.2012.00073.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
527 Jiang ZG, Tsugawa Y, Tapper EB, Lai M, Afdhal N, Robson SC, Mukamal KJ. Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. Aliment Pharmacol Ther 2015;42:106-16. [DOI: 10.1111/apt.13216] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
528 Masuoka HC, Mott J, Bronk SF, Werneburg NW, Akazawa Y, Kaufmann SH, Gores GJ. Mcl-1 degradation during hepatocyte lipoapoptosis. J Biol Chem 2009;284:30039-48. [PMID: 19734538 DOI: 10.1074/jbc.M109.039545] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
529 Babusik P, Bilal M, Duris I. Nonalcoholic fatty liver disease of two ethnic groups in Kuwait: comparison of prevalence and risk factors. Med Princ Pract. 2012;21:56-62. [PMID: 22024606 DOI: 10.1159/000331591] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
530 Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, Hobbs HH. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A. 2010;107:7892-7897. [PMID: 20385813 DOI: 10.1073/pnas.1003585107] [Cited by in Crossref: 248] [Cited by in F6Publishing: 240] [Article Influence: 20.7] [Reference Citation Analysis]
531 Fujita N, Nishie A, Asayama Y, Ishigami K, Ushijima Y, Takayama Y, Okamoto D, Shirabe K, Yoshizumi T, Kotoh K, Furusyo N, Hida T, Oda Y, Fujioka T, Honda H. Fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment using computed tomography volumetry. World J Gastroenterol 2016; 22(40): 8949-8955 [PMID: 27833386 DOI: 10.3748/wjg.v22.i40.8949] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
532 Ooi E, Adams L, Zhu K, Lewis J, Kerr D, Meng X, Solah V, Devine A, Binns C, Prince R. Consumption of a whey protein-enriched diet may prevent hepatic steatosis associated with weight gain in elderly women. Nutrition, Metabolism and Cardiovascular Diseases 2015;25:388-95. [DOI: 10.1016/j.numecd.2014.11.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
533 Posadas-sánchez R, Ocampo-arcos WA, López-uribe ÁR, Posadas-romero C, Villarreal-molina T, León EÁ, Pérez-hernández N, Rodríguez-pérez JM, Cardoso-saldaña G, Medina-urrutia A, Vargas-alarcón G. Hepatic lipase (LIPC) C-514T gene polymorphism is associated with cardiometabolic parameters and cardiovascular risk factors but not with fatty liver in Mexican population. Experimental and Molecular Pathology 2015;98:93-8. [DOI: 10.1016/j.yexmp.2014.12.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
534 Bellarosa C, Bedogni G, Bianco A, Cicolini S, Caroli D, Tiribelli C, Sartorio A. Association of Serum Bilirubin Level with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study of 1672 Obese Children. J Clin Med 2021;10:2812. [PMID: 34202304 DOI: 10.3390/jcm10132812] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
535 Mouralidarane A, Lin CI, Suleyman N, Soeda J, Oben JA. Practical management of the increasing burden of non-alcoholic fatty liver disease. Frontline Gastroenterol 2010;1:149-55. [PMID: 28839568 DOI: 10.1136/fg.2009.000935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
536 Piña-zentella RM, Rosado JL, Gallegos-corona MA, Madrigal-pérez LA, García OP, Ramos-gomez M. Lycopene Improves Diet-Mediated Recuperation in Rat Model of Nonalcoholic Fatty Liver Disease. Journal of Medicinal Food 2016;19:607-14. [DOI: 10.1089/jmf.2015.0123] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
537 Valenti L, Moscatiello S, Vanni E, Fracanzani AL, Bugianesi E, Fargion S, Marchesini G. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. QJM. 2011;104:141-149. [PMID: 20851820 DOI: 10.1093/qjmed/hcq170] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
538 Tu S, Zhao R, Fang H, Wang L, Shao A, Sheng J. Association between Non-Alcoholic Fatty Liver Disease and Intracerebral Hemorrhage. Cell Transplant 2019;28:1033-8. [PMID: 30922067 DOI: 10.1177/0963689719840025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
539 Shapses M, Tang L, Layne A, Beri A, Rotman Y. Fatty Liver Is an Independent Risk Factor for Delayed Recovery from Anesthesia. Hepatol Commun 2021;5:1848-59. [PMID: 34558821 DOI: 10.1002/hep4.1772] [Reference Citation Analysis]
540 Heeringa M, Hastings A, Yamazaki S, de Koning P. Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects? Biomark Med. 2012;6:743-757. [PMID: 23227839 DOI: 10.2217/bmm.12.87] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
541 Uetake Y, Ikeda H, Irie R, Tejima K, Matsui H, Ogura S, Wang H, Mu S, Hirohama D, Ando K, Sawamura T, Yatomi Y, Fujita T, Shimosawa T. High-salt in addition to high-fat diet may enhance inflammation and fibrosis in liver steatosis induced by oxidative stress and dyslipidemia in mice. Lipids Health Dis 2015;14:6. [PMID: 25888871 DOI: 10.1186/s12944-015-0002-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
542 Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230:258-267. [PMID: 24075754 DOI: 10.1016/j.atherosclerosis.2013.07.052] [Cited by in Crossref: 190] [Cited by in F6Publishing: 188] [Article Influence: 21.1] [Reference Citation Analysis]
543 Asakawa M, Mitsui H, Akihisa M, Sekine T, Niitsu Y, Kobayashi A, Miyake A, Hashimoto N, Kawamura M, Ogawa Y. Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury. Springerplus 2015;4:346. [PMID: 26191473 DOI: 10.1186/s40064-015-1135-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
544 Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, Chiu CC, Chuang WL, Tsai TR, Yu ML. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol. 2007;22:2118-2123. [PMID: 18031368 DOI: 10.1111/j.1440-1746.2006.04698.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 6.9] [Reference Citation Analysis]
545 Htun KT, Pan J, Pasanta D, Tungjai M, Udomtanakunchai C, Petcharoen T, Chamta N, Kosicharoen S, Chukua K, Lai C, Kothan S. Advanced Molecular Imaging (MRI/MRS/1H NMR) for Metabolic Information in Young Adults with Health Risk Obesity. Life (Basel) 2021;11:1035. [PMID: 34685406 DOI: 10.3390/life11101035] [Reference Citation Analysis]
546 Bacha F, Cheng P, Gal RL, Beaulieu LC, Kollman C, Adolph A, Shoemaker AH, Wolf R, Klingensmith GJ, Tamborlane WV. Racial and Ethnic Disparities in Comorbidities in Youth With Type 2 Diabetes in the Pediatric Diabetes Consortium (PDC). Diabetes Care 2021:dc210143. [PMID: 34475033 DOI: 10.2337/dc21-0143] [Reference Citation Analysis]
547 Shiffman M, Freilich B, Vuppalanchi R, Watt K, Chan JL, Spada A, Hagerty DT, Schiff E. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;49:64-73. [PMID: 30430605 DOI: 10.1111/apt.15030] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
548 Lyall MJ, Thomson JP, Cartier J, Ottaviano R, Kendall TJ, Meehan RR, Drake AJ. Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation. Epigenetics 2020;15:61-71. [PMID: 31389294 DOI: 10.1080/15592294.2019.1649527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
549 Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol 2015; 7(3): 315-326 [PMID: 25848461 DOI: 10.4254/wjh.v7.i3.315] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
550 Tovar AR, Torre-Villalvazo I, Ochoa M, Elías AL, Ortíz V, Aguilar-Salinas CA, Torres N. Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J Lipid Res 2005;46:1823-32. [PMID: 15995177 DOI: 10.1194/jlr.M500067-JLR200] [Cited by in Crossref: 106] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
551 Zhang Y, Kim DK, Jung YS, Kim YH, Lee YS, Kim J, Jeong WI, Lee IK, Cho SJ, Dooley S, Lee CH, Choi HS. Inverse agonist of ERRγ reduces cannabinoid receptor type 1-mediated induction of fibrinogen synthesis in mice with a high-fat diet-intoxicated liver. Arch Toxicol 2018;92:2885-96. [PMID: 30019168 DOI: 10.1007/s00204-018-2270-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
552 Zelber-Sagi S, Ben-Assuli O, Rabinowich L, Goldstein A, Magid A, Shalev V, Shibolet O, Chodick G. The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort. Liver Int. 2015;35:2408-2415. [PMID: 25845417 DOI: 10.1111/liv.12842] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
553 Varma A, Trudeau S, Zhou Y, Jafri SM, Krajenta R, Lamerato L, Brown K, Luzzi V, Lu M, Gordon SC. African Americans Demonstrate Significantly Lower Serum Alanine Aminotransferase Compared to Non-African Americans. J Racial Ethn Health Disparities 2020. [PMID: 33230736 DOI: 10.1007/s40615-020-00916-2] [Reference Citation Analysis]
554 Kunutsor SK, Bakker SJL, Blokzijl H, Dullaart RPF. Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: Interrelationship with age. Clin Chim Acta. 2017;466:54-60. [PMID: 28082024 DOI: 10.1016/j.cca.2017.01.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
555 Manoria P, Inamdar S, Kumar R. Hepatobiliary dysfunction in Type-2 diabetes mellitus. J Family Med Prim Care 2017;6:563-7. [PMID: 29417009 DOI: 10.4103/2249-4863.222018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
556 Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007;22:778-787. [PMID: 17565630 DOI: 10.1111/j.1440-1746.2007.05001.x] [Cited by in Crossref: 208] [Cited by in F6Publishing: 201] [Article Influence: 13.9] [Reference Citation Analysis]
557 Bertasso IM, Pietrobon CB, Lopes BP, Peixoto TC, Soares PN, Oliveira E, Manhães AC, Bonfleur ML, Balbo SL, Cabral SS, Gabriel Kluck GE, Atella GC, Gaspar de Moura E, Lisboa PC. Programming of hepatic lipid metabolism in a rat model of postnatal nicotine exposure – Sex-related differences. Environmental Pollution 2020;258:113781. [DOI: 10.1016/j.envpol.2019.113781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
558 Bugianesi E, Bellentani S, Bedogni G, Tiribelli C. Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Annals of Hepatology 2008;7:157-60. [DOI: 10.1016/s1665-2681(19)31873-3] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
559 Egan CE, Daugherity EK, Rogers AB, Abi Abdallah DS, Denkers EY, Maurer KJ. CCR2 and CD44 promote inflammatory cell recruitment during fatty liver formation in a lithogenic diet fed mouse model. PLoS One 2013;8:e65247. [PMID: 23762326 DOI: 10.1371/journal.pone.0065247] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
560 Kamada Y, Fujii H, Fujii H, Sawai Y, Doi Y, Uozumi N, Mizutani K, Akita M, Sato M, Kida S. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics Clin Appl. 2013;7:648-656. [PMID: 23775887 DOI: 10.1002/prca.201200137] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
561 Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep 2019;1:214-26. [PMID: 32039372 DOI: 10.1016/j.jhepr.2019.04.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
562 Moriyama K, Urata N, Masuda Y, Oda K, Okuno C, Yamada C, Takashimizu S, Kubo A, Kishimoto N, Nishizaki Y. Usefulness of Triglyceride to High-Density Lipoprotein Ratio and Alanine Aminotransferase for Predicting Insulin Resistance and Metabolic Syndrome in the Japanese Population. Metab Syndr Relat Disord 2021;19:225-32. [PMID: 33577395 DOI: 10.1089/met.2020.0121] [Reference Citation Analysis]
563 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digestive and Liver Disease 2009;41:615-25. [DOI: 10.1016/j.dld.2009.01.004] [Cited by in Crossref: 174] [Cited by in F6Publishing: 174] [Article Influence: 13.4] [Reference Citation Analysis]
564 Lara-Castro C, Garvey WT. Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome. Endocrinol Metab Clin North Am 2008;37:841-56. [PMID: 19026935 DOI: 10.1016/j.ecl.2008.09.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 8.0] [Reference Citation Analysis]
565 Garner CJ, Conn CA, Cohen D, Luo L, Castillo JJ, Shah VO, Garver WS. NAFLD Susceptibility Genes and their Association with Type 2 Diabetes and Obesity in a New Mexico Population. J Diabetes Obes 2015;2. [PMID: 28596988 DOI: 10.15436/2376-0494.15.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
566 Varganova DL, Pavlov CS, Casazza G, Nikolova D, Gluud C; Cochrane Hepato-Biliary Group. Essential phospholipids for people with non-alcoholic fatty liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
567 Goessling W, Massaro JM, Vasan RS, D'Agostino RB, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008;135:1935-1944, 1944.e1. [PMID: 19010326 DOI: 10.1053/j.gastro.2008.09.018] [Cited by in Crossref: 213] [Cited by in F6Publishing: 198] [Article Influence: 15.2] [Reference Citation Analysis]
568 Roden M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2:335-348. [PMID: 16932311 DOI: 10.1038/ncpendmet0190] [Cited by in Crossref: 259] [Cited by in F6Publishing: 242] [Article Influence: 16.2] [Reference Citation Analysis]
569 De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM, Foster GR, Syn WK, Alazawi W. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Frontline Gastroenterol 2018;9:115-21. [PMID: 29588839 DOI: 10.1136/flgastro-2017-100865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
570 Traber MG, Mah E, Leonard SW, Bobe G, Bruno RS. Metabolic syndrome increases dietary α-tocopherol requirements as assessed using urinary and plasma vitamin E catabolites: a double-blind, crossover clinical trial. Am J Clin Nutr 2017;105:571-9. [PMID: 28077381 DOI: 10.3945/ajcn.116.138495] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
571 Sturzeneker MC, Ioshii SO, Villela Baroncini LA, Précoma DB. Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia. Atherosclerosis 2011;216:97-102. [PMID: 21338989 DOI: 10.1016/j.atherosclerosis.2011.01.047] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
572 Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis. 2012;16:567-585. [PMID: 22824481 DOI: 10.1016/j.cld.2012.05.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
573 Skeldon AM, Morizot A, Douglas T, Santoro N, Kursawe R, Kozlitina J, Caprio S, Mehal WZ, Saleh M. Caspase-12, but Not Caspase-11, Inhibits Obesity and Insulin Resistance. J Immunol 2016;196:437-47. [PMID: 26582949 DOI: 10.4049/jimmunol.1501529] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
574 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol 2017; 9(16): 715-732 [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 304] [Cited by in F6Publishing: 267] [Article Influence: 60.8] [Reference Citation Analysis]
575 Bhala N, Bhopal R, Brock A, Griffiths C, Wild S. Alcohol-related and hepatocellular cancer deaths by country of birth in England and Wales: analysis of mortality and census data. Journal of Public Health 2009;31:250-7. [DOI: 10.1093/pubmed/fdp014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
576 Birjandi M, Ayatollahi SM, Pourahmad S, Safarpour AR. Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. Iran Red Crescent Med J 2016;18:e32858. [PMID: 28191344 DOI: 10.5812/ircmj.32858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
577 Serai SD, Dillman JR, Trout AT. Proton Density Fat Fraction Measurements at 1.5- and 3-T Hepatic MR Imaging: Same-Day Agreement among Readers and across Two Imager Manufacturers. Radiology 2017;284:244-54. [PMID: 28212052 DOI: 10.1148/radiol.2017161786] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
578 Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021;17:662-70. [PMID: 34417588 DOI: 10.1038/s41574-021-00538-6] [Reference Citation Analysis]
579 Speakman JR, Westerterp KR. A mathematical model of weight loss under total starvation: evidence against the thrifty-gene hypothesis. Dis Model Mech 2013;6:236-51. [PMID: 22864023 DOI: 10.1242/dmm.010009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
580 Cotrim HP, Parise ER, Oliveira CP, Leite N, Martinelli A, Galizzi J, de Càssia Silva R, Mattos Â, Pereira L, Amorim W, Ivantes C, Souza F, Costa M, Maia L, Pessoa M, Oliveira F. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Annals of Hepatology 2011;10:33-7. [DOI: 10.1016/s1665-2681(19)31584-4] [Cited by in Crossref: 33] [Article Influence: 3.0] [Reference Citation Analysis]
581 DeSantis DA, Ko CW, Wang L, Lee P, Croniger CM. Constitutive Activation of the Nlrc4 Inflammasome Prevents Hepatic Fibrosis and Promotes Hepatic Regeneration after Partial Hepatectomy. Mediators Inflamm 2015;2015:909827. [PMID: 26635450 DOI: 10.1155/2015/909827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
582 García-Román R, Francés R. Acetaminophen-Induced Liver Damage in Hepatic Steatosis. Clin Pharmacol Ther 2020;107:1068-81. [PMID: 31638270 DOI: 10.1002/cpt.1701] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
583 Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol 2015; 7(3): 575-582 [PMID: 25848481 DOI: 10.4254/wjh.v7.i3.575] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
584 Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2013;27:1-13. [PMID: 23554788 DOI: 10.7555/jbr.27.20120077] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
585 Ostovaneh MR, Ambale-Venkatesh B, Fuji T, Bakhshi H, Shah R, Murthy VL, Tracy RP, Guallar E, Wu CO, Bluemke DA, Lima JAC. Association of Liver Fibrosis With Cardiovascular Diseases in the General Population: The Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging 2018;11:e007241. [PMID: 29523555 DOI: 10.1161/CIRCIMAGING.117.007241] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 9.3] [Reference Citation Analysis]
586 Gibson PS, Lang S, Dhawan A, Fitzpatrick E, Blumfield ML, Truby H, Hart KH, Moore JB. Systematic Review: Nutrition and Physical Activity in the Management of Paediatric Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2017;65:141-149. [PMID: 28737568 DOI: 10.1097/mpg.0000000000001624] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 5.8] [Reference Citation Analysis]
587 Wang CY, Lu W, Hu DS, Wang GD, Cheng XJ. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B. World J Gastroenterol 2014; 20(30): 10585-10590 [PMID: 25132779 DOI: 10.3748/wjg.v20.i30.10585] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
588 Ahmed A, Wong RJ, Harrison SA. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol. 2015;13:2062-2070. [PMID: 26226097 DOI: 10.1016/j.cgh.2015.07.029] [Cited by in Crossref: 159] [Cited by in F6Publishing: 137] [Article Influence: 22.7] [Reference Citation Analysis]
589 Chen P, Li Y, Xiao L. Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR. Exp Ther Med 2021;22:1109. [PMID: 34504563 DOI: 10.3892/etm.2021.10543] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
590 Du T, Sun X, Yuan G, Zhou X, Lu H, Lin X, Yu X. Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2017;27:63-9. [PMID: 27956025 DOI: 10.1016/j.numecd.2016.10.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
591 Santoro N, Feldstein AE, Enoksson E, Pierpont B, Kursawe R, Kim G, Caprio S. The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variants. Diabetes Care 2013;36:1353-60. [PMID: 23275357 DOI: 10.2337/dc12-1791] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
592 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
593 Fengler VH, Macheiner T, Kessler SM, Czepukojc B, Gemperlein K, Müller R, Kiemer AK, Magnes C, Haybaeck J, Lackner C, Sargsyan K. Susceptibility of Different Mouse Wild Type Strains to Develop Diet-Induced NAFLD/AFLD-Associated Liver Disease. PLoS One 2016;11:e0155163. [PMID: 27167736 DOI: 10.1371/journal.pone.0155163] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
594 Feitosa MF, Reiner AP, Wojczynski MK, Graff M, North KE, Carr JJ, Borecki IB. Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis. 2013;227:420-424. [PMID: 23390892 DOI: 10.1016/j.atherosclerosis.2013.01.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
595 Kallwitz ER, Guzman G, TenCate V, Vitello J, Layden-Almer J, Berkes J, Patel R, Layden TJ, Cotler SJ. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am J Gastroenterol. 2009;104:64-69. [PMID: 19098851 DOI: 10.1038/ajg.2008.12] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
596 Gutiérrez-vidal R, Vega-badillo J, Reyes-fermín LM, Hernández-pérez HA, Sánchez-muñoz F, López-álvarez GS, Larrieta-carrasco E, Fernández-silva I, Méndez-sánchez N, Tovar AR, Villamil-ramírez H, Mejía-domínguez AM, Villarreal-molina T, Hernández-pando R, Campos-pérez F, Aguilar-salinas CA, Canizales-quinteros S. SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women. Annals of Hepatology 2015;14:666-74. [DOI: 10.1016/s1665-2681(19)30761-6] [Cited by in Crossref: 19] [Article Influence: 2.7] [Reference Citation Analysis]
597 Tiwari-Heckler S, Yee EU, Yalcin Y, Park J, Nguyen DT, Gao W, Csizmadia E, Afdhal N, Mukamal KJ, Robson SC, Lai M, Schwartz RE, Jiang ZG. Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease. Cell Rep 2021;37:109897. [PMID: 34706243 DOI: 10.1016/j.celrep.2021.109897] [Reference Citation Analysis]
598 Isokuortti E, Zhou Y, Peltonen M, Bugianesi E, Clement K, Bonnefont-Rousselot D, Lacorte JM, Gastaldelli A, Schuppan D, Schattenberg JM, Hakkarainen A, Lundbom N, Jousilahti P, Männistö S, Keinänen-Kiukaanniemi S, Saltevo J, Anstee QM, Yki-Järvinen H. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. Diabetologia 2017;60:1873-82. [PMID: 28660493 DOI: 10.1007/s00125-017-4340-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
599 Loomba R, Hwang SJ, O'Donnell CJ, Ellison RC, Vasan RS, D'Agostino RB Sr, Liang TJ, Fox CS. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. Gastroenterology 2008;134:953-9. [PMID: 18395076 DOI: 10.1053/j.gastro.2008.01.037] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
600 Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-Stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V. Vitamin D Deficiency Is Associated with Increased Risk of Non-alcoholic Steatohepatitis in Adults with Non-alcoholic Fatty Liver Disease: Possible Role for MAPK and NF-kappaB? Am J Gastroenterol. 2016;111:852-863. [PMID: 27002799 DOI: 10.1038/ajg.2016.51] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
601 Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-1405. [PMID: 25557690 DOI: 10.1002/hep.27678] [Cited by in Crossref: 213] [Cited by in F6Publishing: 194] [Article Influence: 30.4] [Reference Citation Analysis]
602 Ferslew BC, Xie G, Johnston CK, Su M, Stewart PW, Jia W, Brouwer AS 4th. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci. 2015;60:3318-3328. [PMID: 26138654 DOI: 10.1007/s10620-015-3776-8] [Cited by in Crossref: 159] [Cited by in F6Publishing: 153] [Article Influence: 22.7] [Reference Citation Analysis]
603 Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519-1523. [PMID: 21700865 DOI: 10.1126/science.1204265] [Cited by in Crossref: 1296] [Cited by in F6Publishing: 1266] [Article Influence: 117.8] [Reference Citation Analysis]
604 Paul J, Venugopal RV, Peter L, Hussain S, Naresh Kumar Shetty K, Shetti MP. Effects of lifestyle modification on liver enzyme and Fibroscan in Indian patients with non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf) 2018;6:49-53. [PMID: 29479443 DOI: 10.1093/gastro/gox020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
605 Parry SA, Hodson L. Influence of dietary macronutrients on liver fat accumulation and metabolism. J Investig Med 2017;65:1102-15. [PMID: 28947639 DOI: 10.1136/jim-2017-000524] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 11.0] [Reference Citation Analysis]
606 Pickhardt PJ, Park SH, Hahn L, Lee SG, Bae KT, Yu ES. Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol. 2012;22:1075-1082. [PMID: 22138733 DOI: 10.1007/s00330-011-2349-2] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
607 Yang W, Xu H, Yu X, Wang Y. Association between retinal artery lesions and nonalcoholic fatty liver disease. Hepatol Int 2015;9:278-82. [PMID: 25788195 DOI: 10.1007/s12072-015-9607-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
608 Afsari A, Lee E, Shokrani B, Boortalary T, Sherif ZA, Nouraie M, Laiyemo AO, Alkhalloufi K, Brim H, Ashktorab H. Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C. Dig Dis Sci 2017;62:2159-65. [PMID: 28612194 DOI: 10.1007/s10620-017-4626-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
609 Ma Y, Belyaeva OV, Brown PM, Fujita K, Valles K, Karki S, de Boer YS, Koh C, Chen Y, Du X, Handelman SK, Chen V, Speliotes EK, Nestlerode C, Thomas E, Kleiner DE, Zmuda JM, Sanyal AJ, Kedishvili NY, Liang TJ, Rotman Y; (for the Nonalcoholic Steatohepatitis Clinical Research Network). 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology 2019;69:1504-19. [PMID: 30415504 DOI: 10.1002/hep.30350] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 35.3] [Reference Citation Analysis]
610 Owada Y, Tamura T, Tanoi T, Ozawa Y, Shimizu Y, Hisakura K, Matsuzaka T, Shimano H, Nakano N, Sakashita S. Novel non-alcoholic steatohepatitis model with histopathological and insulin-resistant features. Pathol Int. 2018;68:12-22. [PMID: 29154469 DOI: 10.1111/pin.12612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
611 Su Z, Shan H, He B, Lv W, Meng X, Wang J, Zhu K, Yang Y, Chen G. Selection of the most powerful predictors for the evaluation of hepatic steatosis grade: An experimental study. European Journal of Radiology 2009;72:118-24. [DOI: 10.1016/j.ejrad.2008.06.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
612 O'Flanagan CH, Bowers LW, Hursting SD. A weighty problem: metabolic perturbations and the obesity-cancer link. Horm Mol Biol Clin Investig 2015;23:47-57. [PMID: 26167982 DOI: 10.1515/hmbci-2015-0022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
613 Chen L, Liu L, Li C, Hu C, Su F, Liu R, Zeng M, Zhao D, Liu J, Guo Y, Long J. A mix of apple pomace polysaccharide improves mitochondrial function and reduces oxidative stress in the liver of high-fat diet-induced obese mice. Mol Nutr Food Res 2017;61:1600433. [DOI: 10.1002/mnfr.201600433] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
614 Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Adv Nutr. 2017;8:253-265. [PMID: 28298270 DOI: 10.3945/an.116.013730] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
615 Fahim SM, Chowdhury MAB, Alam S. Non-alcoholic fatty liver disease (NAFLD) among underweight adults. Clinical Nutrition ESPEN 2020;38:80-5. [DOI: 10.1016/j.clnesp.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
616 Krššák M. Novel labeling approaches for the assessment of human hepatic metabolism by in vivo magnetic resonance spectroscopy. Hepatology 2014;59:2077-9. [PMID: 24700320 DOI: 10.1002/hep.27091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
617 Martin K, Hatab A, Athwal VS, Jokl E, Piper Hanley K. Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications. Curr Diab Rep 2021;21:8. [PMID: 33544287 DOI: 10.1007/s11892-021-01377-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
618 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-8. [PMID: 25018867 DOI: 10.1136/flgastro-2013-100403] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 15.0] [Reference Citation Analysis]
619 Kurt Z, Barrere-Cain R, LaGuardia J, Mehrabian M, Pan C, Hui ST, Norheim F, Zhou Z, Hasin Y, Lusis AJ, Yang X. Tissue-specific pathways and networks underlying sexual dimorphism in non-alcoholic fatty liver disease. Biol Sex Differ 2018;9:46. [PMID: 30343673 DOI: 10.1186/s13293-018-0205-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
620 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 61] [Article Influence: 17.4] [Reference Citation Analysis]
621 Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011;46:63-9. [DOI: 10.1007/s00535-010-0311-8] [Cited by in Crossref: 152] [Cited by in F6Publishing: 137] [Article Influence: 12.7] [Reference Citation Analysis]
622 Cengiz M, Candır BA, Yılmaz G, Akyol G, Ozenirler S. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage? World J Gastroenterol 2013; 19(42): 7412-7418 [PMID: 24259972 DOI: 10.3748/wjg.v19.i42.7412] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
623 Bergqvist CJ, Skoien R, Horsfall L, Clouston AD, Jonsson JR, Powell EE. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern Med J. 2013;43:247-253. [PMID: 22646061 DOI: 10.1111/j.1445-5994.2012.02848.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
624 Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883-889. [PMID: 17402991 DOI: 10.1111/j.1365-2036.2007.03246.x] [Cited by in Crossref: 239] [Cited by in F6Publishing: 232] [Article Influence: 15.9] [Reference Citation Analysis]
625 Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment. Curr Diab Rep. 2008;8:25-30. [PMID: 18366995 DOI: 10.1007/s11892-008-0006-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
626 Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197-211. [PMID: 28303724 DOI: 10.1080/03602532.2017.1293683] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 27.4] [Reference Citation Analysis]
627 Liu ZL, Xie LZ, Zhu J, Li GQ, Grant SJ, Liu JP. Herbal medicines for fatty liver diseases. Cochrane Database Syst Rev. 2013;(8):CD009059. [PMID: 23975682 DOI: 10.1002/14651858.cd009059.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
628 Singh RG, Yoon HD, Wu LM, Lu J, Plank LD, Petrov MS. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. Metabolism. 2017;69:1-13. [PMID: 28285638 DOI: 10.1016/j.metabol.2016.12.012] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 13.8] [Reference Citation Analysis]
629 Barchetta I, Cimini FA, Leonetti F, Capoccia D, Di Cristofano C, Silecchia G, Orho-melander M, Melander O, Cavallo MG. Increased Plasma Proneurotensin Levels Identify NAFLD in Adults With and Without Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism 2018;103:2253-60. [DOI: 10.1210/jc.2017-02751] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
630 Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2010;138:905-912. [PMID: 19931264 DOI: 10.1053/j.gastro.2009.11.013] [Cited by in Crossref: 182] [Cited by in F6Publishing: 170] [Article Influence: 14.0] [Reference Citation Analysis]
631 Lichtenstein D, Mentz A, Schmidt FF, Luckert C, Buhrke T, Marx-stoelting P, Kalinowski J, Albaum SP, Joos TO, Poetz O, Braeuning A. Transcript and protein marker patterns for the identification of steatotic compounds in human HepaRG cells. Food and Chemical Toxicology 2020;145:111690. [DOI: 10.1016/j.fct.2020.111690] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
632 Zhang YL, Hernandez-Ono A, Siri P, Weisberg S, Conlon D, Graham MJ, Crooke RM, Huang LS, Ginsberg HN. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem 2006;281:37603-15. [PMID: 16971390 DOI: 10.1074/jbc.M604709200] [Cited by in Crossref: 113] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
633 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016; 7(2): 211-217 [PMID: 27190693 DOI: 10.4291/wjgp.v7.i2.211] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 7.5] [Reference Citation Analysis]
634 Sanyal AJ. The fibrosis benefit index for assessment of therapeutic benefit in non-alcoholic steatohepatitis. The Lancet Gastroenterology & Hepatology 2017;2:241-3. [DOI: 10.1016/s2468-1253(17)30005-5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
635 Cazanave SC, Sanyal AJ. Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease. In: Ntambi JM, editor. Hepatic De Novo Lipogenesis and Regulation of Metabolism. Cham: Springer International Publishing; 2016. pp. 101-29. [DOI: 10.1007/978-3-319-25065-6_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
636 Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008; 14(22): 3476-3483 [PMID: 18567074 DOI: 10.3748/wjg.14.3476] [Cited by in CrossRef: 169] [Cited by in F6Publishing: 158] [Article Influence: 12.1] [Reference Citation Analysis]
637 Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009;13:631-647. [PMID: 19818310 DOI: 10.1016/j.cld.2009.07.007] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 6.7] [Reference Citation Analysis]
638 Valenti L, Dongiovanni P, Fargion S. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(29): 3782-3786 [PMID: 22876027 DOI: 10.3748/wjg.v18.i29.3782] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
639 Wong WK, Chan WK. Nonalcoholic Fatty Liver Disease: A Global Perspective. Clin Ther 2021;43:473-99. [PMID: 33526312 DOI: 10.1016/j.clinthera.2021.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
640 Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, Sanyal AJ. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134:568-576. [PMID: 18082745 DOI: 10.1053/j.gastro.2007.10.039] [Cited by in Crossref: 383] [Cited by in F6Publishing: 356] [Article Influence: 25.5] [Reference Citation Analysis]
641 Bril F, Lomonaco R, Cusi K. The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. Clinical Lipidology 2012;7:471-81. [DOI: 10.2217/clp.12.47] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
642 Gkolfakis P, Dimitriadis G, Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2015;14:572-81. [PMID: 26663004 DOI: 10.1016/s1499-3872(15)60026-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
643 Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, Gill PS, Neuberger JM, Lilford RJ, Newsome PN. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012;56:234-40. [PMID: 21703178 DOI: 10.1016/j.jhep.2011.03.020] [Cited by in Crossref: 170] [Cited by in F6Publishing: 149] [Article Influence: 15.5] [Reference Citation Analysis]
644 Desterke C, Chiappini F. Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway. Int J Mol Sci 2019;20:E5594. [PMID: 31717414 DOI: 10.3390/ijms20225594] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
645 Mazhar SM, Shiehmorteza M, Sirlin CB. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009;7:135-40. [PMID: 19118644 DOI: 10.1016/j.cgh.2008.11.023] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 6.6] [Reference Citation Analysis]
646 Sakhaee K, Maalouf NM. Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol 2008;28:174-80. [PMID: 18359398 DOI: 10.1016/j.semnephrol.2008.01.010] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
647 Tziomalos K, Athyros VG, Paschos P, Karagiannis A. Nonalcoholic fatty liver disease and statins. Metabolism. 2015;64:1215-1223. [PMID: 26234727 DOI: 10.1016/j.metabol.2015.07.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
648 Daly AK. Relevance of CYP2E1 to non-alcoholic fatty liver disease. Subcell Biochem 2013;67:165-75. [PMID: 23400921 DOI: 10.1007/978-94-007-5881-0_5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
649 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017; 8(2): 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 9.4] [Reference Citation Analysis]
650 Granér M, Nyman K, Siren R, Pentikäinen MO, Lundbom J, Hakkarainen A, Lauerma K, Lundbom N, Nieminen MS, Taskinen M. Ectopic Fat Depots and Left Ventricular Function in Nondiabetic Men With Nonalcoholic Fatty Liver Disease. Circ Cardiovasc Imaging 2015;8. [DOI: 10.1161/circimaging.114.001979] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 6.9] [Reference Citation Analysis]
651 Duvnjak M, Lerotić I, Baršić N, Tomašić V, Jukić LV, Velagić V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13(34): 4539-4550 [PMID: 17729403 DOI: 10.3748/wjg.v13.i34.4539] [Cited by in CrossRef: 157] [Cited by in F6Publishing: 142] [Article Influence: 10.5] [Reference Citation Analysis]
652 Irwan R, Edens MA, Sijens PE. Assessment of the variations in fat content in normal liver using a fast MR imaging method in comparison with results obtained by spectroscopic imaging. Eur Radiol 2008;18:806-13. [PMID: 17999066 DOI: 10.1007/s00330-007-0801-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
653 Goceri E, Shah ZK, Layman R, Jiang X, Gurcan MN. Quantification of liver fat: A comprehensive review. Comput Biol Med 2016;71:174-89. [PMID: 26945465 DOI: 10.1016/j.compbiomed.2016.02.013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
654 Pacifico L, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi A. MRI and ultrasound for hepatic fat quantification:relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr. 2007;96:542-547. [PMID: 17306008 DOI: 10.1111/j.1651-2227.2007.00186.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 86] [Article Influence: 6.0] [Reference Citation Analysis]
655 Gajdošík M, Chadzynski GL, Hangel G, Mlynárik V, Chmelík M, Valkovič L, Bogner W, Pohmann R, Scheffler K, Trattnig S, Krššák M. Ultrashort-TE stimulated echo acquisition mode (STEAM) improves the quantification of lipids and fatty acid chain unsaturation in the human liver at 7 T. NMR Biomed 2015;28:1283-93. [PMID: 26313737 DOI: 10.1002/nbm.3382] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
656 Parry SA, Hodson L. Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review. Adv Ther 2020;37:1381-406. [PMID: 32146704 DOI: 10.1007/s12325-020-01281-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
657 Broermann A, Schmid R, Gabrielyan O, Sakowski M, Eisele C, Keller S, Wolff M, Baum P, Stierstorfer B, Huber J, Krämer BK, Hocher B, Streicher R, Delić D. Exosomal miRNAs as Potential Biomarkers to Monitor Phosphodiesterase 5 Inhibitor Induced Anti-Fibrotic Effects on CCl4 Treated Rats. Int J Mol Sci 2020;22:E382. [PMID: 33396535 DOI: 10.3390/ijms22010382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
658 Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2011;5:253-263. [PMID: 21476920 DOI: 10.1586/egh.11.18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
659 Ozturk A, Olson MC, Samir AE, Venkatesh SK. Liver fibrosis assessment: MR and US elastography. Abdom Radiol (NY) 2021. [PMID: 34687329 DOI: 10.1007/s00261-021-03269-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
660 Marlatt KL, Redman LM, Beyl RA, Smith SR, Champagne CM, Yi F, Lovejoy JC. Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study. Am J Obstet Gynecol 2020;222:365.e1-365.e18. [PMID: 31610152 DOI: 10.1016/j.ajog.2019.09.051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
661 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
662 Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, Cusi K. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.J Clin Endocrinol Metab. 2017;102:2950-2961. [PMID: 28575232 DOI: 10.1210/jc.2017-00867] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
663 Mashek DG. Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr 2013;4:697-710. [PMID: 24228201 DOI: 10.3945/an.113.004648] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.9] [Reference Citation Analysis]
664 Mazi TA, Borkowski K, Newman JW, Fiehn O, Bowlus CL, Sarkar S, Matsukuma K, Ali MR, Kieffer DA, Wan YY, Stanhope KL, Havel PJ, Medici V. Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. Free Radic Biol Med 2021;172:490-502. [PMID: 34182070 DOI: 10.1016/j.freeradbiomed.2021.06.024] [Reference Citation Analysis]
665 Zhang Y, Kim DK, Lu Y, Jung YS, Lee JM, Kim YH, Lee YS, Kim J, Dewidar B, Jeong WI, Lee IK, Cho SJ, Dooley S, Lee CH, Li X, Choi HS. Orphan nuclear receptor ERRγ is a key regulator of human fibrinogen gene expression. PLoS One 2017;12:e0182141. [PMID: 28750085 DOI: 10.1371/journal.pone.0182141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
666 Rangnekar AS, Lammert F, Igolnikov A, Green RM. Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. Liver Int 2006;26:1000-5. [PMID: 16953841 DOI: 10.1111/j.1478-3231.2006.01314.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
667 Edelman D, Kalia H, Delio M, Alani M, Krishnamurthy K, Abd M, Auton A, Wang T, Wolkoff AW, Morrow BE. Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population. Mol Genet Genomic Med 2015;3:558-69. [PMID: 26740948 DOI: 10.1002/mgg3.168] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
668 Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899-905. [PMID: 15795412 DOI: 10.1503/cmaj.045232] [Cited by in Crossref: 330] [Cited by in F6Publishing: 313] [Article Influence: 19.4] [Reference Citation Analysis]
669 Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116:539-564. [PMID: 19243311 DOI: 10.1042/cs20080253] [Cited by in Crossref: 160] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
670 Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37. [PMID: 21180596 DOI: 10.1177/1756283X09359964] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
671 Chung GE, Yim JY, Kim D, Kwak MS, Yang JI, Park B, An SJ, Kim JS. Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia. J Korean Med Sci 2020;35:e164. [PMID: 32508064 DOI: 10.3346/jkms.2020.35.e164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
672 Choi SY, Park JS, Shon CH, Lee CY, Ryu JM, Son DJ, Hwang BY, Yoo HS, Cho YC, Lee J, Kim JW, Roh YS. Fermented Korean Red Ginseng Extract Enriched in Rd and Rg3 Protects against Non-Alcoholic Fatty Liver Disease through Regulation of mTORC1. Nutrients 2019;11:E2963. [PMID: 31817227 DOI: 10.3390/nu11122963] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
673 Guo F, Ma Y, Kadegowda AKG, Betters JL, Xie P, Liu G, Liu X, Miao H, Ou J, Su X, Zheng Z, Xue B, Shi H, Yu L. Deficiency of liver Comparative Gene Identification-58 causes steatohepatitis and fibrosis in mice. J Lipid Res 2013;54:2109-20. [PMID: 23733885 DOI: 10.1194/jlr.M035519] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
674 Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, Anvari M, Hong D. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:1040-1060.e11. [PMID: 30326299 DOI: 10.1016/j.cgh.2018.10.017] [Cited by in Crossref: 99] [Cited by in F6Publishing: 90] [Article Influence: 24.8] [Reference Citation Analysis]
675 Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-varghese SEK, Macdougall K, Preston T, Tedford MC, Bell JD, Thomas EL, Mt-isa S, Ashby D, Dhillo WS, Bloom SR, Morley WG, Clegg S, Frost G. Effects of elevating colonic propionate on liver fat content in overweight adults with non-alcoholic fatty liver disease: a pilot study. Proc Nutr Soc 2015;74. [DOI: 10.1017/s0029665115000452] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
676 Chen X, Li K, Yip R, Perumalswami P, Branch AD, Lewis S, Del Bello D, Becker BJ, Yankelevitz DF, Henschke CI. Hepatic steatosis in participants in a program of low-dose CT screening for lung cancer. Eur J Radiol 2017;94:174-9. [PMID: 28712697 DOI: 10.1016/j.ejrad.2017.06.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9